專利文獻2及5中，除了使用水溶性之金屬化合物作為凝血劑以外，對於提高血液之吸收速度或提高吸收量之構成並無記載。另一方面，專利文獻3中所記載之吸收性物品中，不僅壓紋之形態不明，而且使血液凝膠化劑集中於壓紋線之末端或沿其端而集中，故而於該部分會形成凝集塊，無法充分地利用吸收體。進而，專利文獻4中，雖然紅血球塊被捕捉至不織網之纖維間，但難以連續地保障利用該機制進行之血液之吸收。進而，關於專利文獻3及專利文獻4中所記載之吸收性物品，雖然記載有可使用包含聚陽離子之流體處理劑，但實際上僅揭示了非離子系之處理材料時之資料。又，該等技術於如下等方面亦不利：由於吸收性物品之與排泄位置對向之部分之因血液凝集物而導致之通液性之降低，故而血液向吸收體之吸收受到阻礙，血液之吸收耗費時間，或血液之吸收量降低。又，專利文獻1～專利文獻5中，對於將血液改質劑用於伴隨防漏槽中產生之正面片材與吸收體之間之剝離而導致防漏性降低之對策無任何記載。 因此，本發明之課題係關於提供一種更有效地表現利用血球凝集劑提高吸收性能之效果的吸收性物品。 又，本發明之課題係關於提供一種可解決先前技術所具有之解決課題之吸收性物品。 以下，一面參照圖式一面對本發明之經血吸收用之吸收性物品基於其較佳之實施形態進行說明。經血吸收用之吸收性物品包含於經期用品中。 作為本發明之第1實施形態之經期衛生棉1(以下，亦稱作「衛生棉1」)如圖1及圖2所示，具備形成肌膚對向面之液體透過性之正面片材2、形成非肌膚對向面之背面片材3、及配置於該等兩片材2、3間之液體保持性之吸收體4。正面片材2、吸收體4及背面片材3經一體化而構成吸收性本體5。於吸收性本體5之長度方向兩側部之正面片材2側配置有側部防漏片材6。側部防漏片材6具有不與正面片材2接合之自由端61、及與正面片材2接合之固定端62，於使用時，固定端62與自由端61之間離開正面片材2，形成防止向側方側漏之防漏袋(未圖示)。於吸收性本體5之非肌膚抵接面設置有用以向短褲之褲襠部固定之本體黏著部(省略圖示)。又，衛生棉1於縱向X上之兩側部具有一對側翼部7。於一對側翼部7之背面片材3側之面設置有用以向短褲之褲襠部之非肌膚對向面固定之側翼部黏著部(省略圖示)。 作為正面片材2、背面片材3、側部防漏片材6，可無特別限制地使用先前用於經期衛生棉等吸收性物品之各種片材等。例如，作為正面片材2，可使用單層或多層結構之不織布或開孔膜等。正面片材2可為於肌膚抵接面側具有凹凸者，又，亦可為於構成纖維之表面附著有油劑者。於正面片材2為多層結構者之情形時，作為該正面片材2，可使用如下之凹凸片材：其具有位於靠近穿著者之肌膚之側之第1纖維層、及位於距穿著者之肌膚較遠之側之第2纖維層，兩纖維層藉由局部地形成之多個接合部而於厚度方向上一體化，第1纖維層上之位於複數個該接合部彼此間之部分凸狀地隆起而形成上述凹凸形狀之凸部。作為凸部為實心結構之凹凸片材，例如可使用日本專利特開2007-182662號公報或日本專利特開2002-187228號公報中所記載者。作為背面片材3，可使用樹脂膜或樹脂膜與不織布與積層體等。背面片材3係使用液體不透過性(亦包括液體難透過性)或撥水性者，亦較佳為使用透濕性之樹脂膜等。作為側部防漏片材6，可使用耐水壓較高之積層不織布、樹脂膜與不織布之積層體等。 如圖1所示，衛生棉1具有對應於穿著者之前後方向之縱向X、及與該縱向X正交之橫向Y。又，衛生棉1於縱向X上具有：具有於寬度方向(橫向)Y中央部與陰道口等穿著者之液體排泄部對向配置之排泄位置部P之排泄部對向部B、較該排泄部對向部B靠穿著者之腹側(前側)配置之前方部A、及較該排泄部對向部B靠穿著者之背側(後側)配置之後方部C。即，衛生棉1於縱向X上被依序區分為前方部A、排泄部對向部B及後方部C。 於本發明之吸收性物品中，肌膚對向面係衛生棉1或其構成構件(例如正面片材2、吸收性芯體41)中之於穿著衛生棉1時朝向穿著者之肌膚側之面，非肌膚對向面係衛生棉1或其構成構件中之於穿著衛生棉1時朝向與肌膚側為相反之側(通常為所穿衣服側)之面。所謂排泄位置部P，係指衛生棉1等吸收性物品之穿著時與穿著者之液體排泄部對向配置而直接被供給經血之部位，通常位於上述排泄部對向部B之縱向X及寬度方向Y之中央部。於本實施形態之衛生棉1中，排泄位置部P成為橢圓形狀，其具有沿著將衛生棉1於寬度方向上等分之沿縱向X延伸之中央線的長軸3 cm、及沿著橫向Y之短軸2 cm。又，於衛生棉1中，於縱向X上，排泄位置部P之中心點較佳為大致位於側翼部之縱向二等分線上。此處，所謂「大致位於」，意指亦可自該二等分線朝前方及後方偏移15 mm，但於該情形時，排泄位置部P亦落在排泄部對向部B內而存在。 於本發明之吸收性物品中，所謂排泄部對向部B，於如本實施形態之衛生棉1般具有所謂之側翼部之情形時，意指於吸收性物品之縱向X上具有側翼部之區域(夾於一側翼部之沿縱向X之根部與另一側翼部之沿縱向X之根部的區域)。又，於吸收性物品不具有側翼部之情形時，意指將吸收性物品摺疊成三折之單個包裝形態時產生沿橫向Y橫截該吸收性物品之2條折曲線(未圖示)而吸收性物品被自縱向X之前端數第1折曲線與第2折曲線包圍的區域。 於衛生棉1中，正面片材2被覆吸收體4之肌膚對向面之全域，背面片材3被覆吸收體4之非肌膚對向面之全域。正面片材2及背面片材3之自吸收體4之縱向X之兩端緣延出之部分相互接合。又，背面片材3及側部防漏片材6之自吸收體4之沿縱向X之兩側緣向橫向Y之外側延出之部分相互接合。以此方式，吸收體4由正面片材2與背面片材3夾持。構成衛生棉1之片材間之接合係使用接著劑、熱密封、超音波密封等任意之接合方法。 於本發明之經期吸收性物品中，於排泄部對向部B，正面片材2陷入至吸收體4內而成之側方防漏槽81於沿縱向X之兩側部連續地延伸而形成。第1實施形態之衛生棉1如圖1所示，於衛生棉1之肌膚對向面上之上述排泄位置部P之周圍具有正面片材2陷入至吸收體4內而成之側方防漏槽81。更具體而言，於衛生棉1之肌膚對向面形成有環狀之防漏槽8，該環狀之防漏槽8具備：沿縱向X延伸之一對側方防漏槽81、81、於前方部A側將一對側方防漏槽81、81之端部彼此連結之前方防漏槽82、及於後方部C側將一對側方防漏槽81、81之端部彼此連結之後方防漏槽83。 一對側方防漏槽81之各者於橫向Y上之隔著排泄位置部P之兩側分別沿衛生棉1之縱向X延伸。一對側方防漏槽81、81較佳為至少於排泄部對向部B中之隔著排泄位置部P之兩側分別沿縱向X延伸。側方防漏槽81較佳為自排泄部對向部B跨及前方部A或後方部B而延伸，更佳為如圖1所示般跨及前方部A、排泄部對向部B及後方部C而延伸。又，一對側方防漏槽81、81較佳為藉由較排泄位置部P通過前方側之前方防漏槽82而前方部A側之端部彼此連結，又，藉由較排泄位置部P通過後方側之後方防漏槽83而後方部C側之端部彼此連結。 一對側方防漏槽81之各者於排泄部對向部B、較佳為隔著排泄位置部P而位於橫向Y之兩側之部分具有具朝橫向Y之外側凸狀地彎曲之俯視形狀的中央圓弧狀部81b，於縱向X上之中央圓弧狀部81b之前後，分別具有具朝橫向Y之外側凸狀地彎曲之俯視形狀的前方圓弧狀部81a及後方圓弧狀部81c。一對側方防漏槽81之各者具有朝橫向Y之外側凸地彎曲之上述3個圓弧狀部(外凸彎曲部)81a、81b、81c於縱向X上三者相連之俯視形狀，中央圓弧狀部81b與前方圓弧狀部81a之連接部及中央圓弧狀部81b與後方圓弧狀部81c之連接部成為一對側方防漏槽81之距離變窄之內縮部。 關於防漏槽8，於側方防漏槽81、前方防漏槽82及後方防漏槽83之任一者中，吸收體4之肌膚對向面側均與正面片材2一併凹陷成槽狀，吸收體4中，形成有防漏槽81、82、83之部位分別與該吸收體4中之隔著該防漏槽81、82、83而位於其兩側之部分相比壓密化。防漏槽8例如可藉由如下方式而形成：對將正面片材2與吸收體4重疊而成者實施加壓、或伴隨加熱及加壓之壓紋加工。防漏槽8之主要作用係抑制衛生棉1之平面方向之液之擴散。 如圖2所示，衛生棉1之吸收體4具有包含紙漿纖維之吸收性芯體41、及被覆該吸收性芯體41之包芯片材42。 本實施形態中之包芯片材42具有：被覆吸收性芯體41之肌膚對向面側之肌膚側部分42a、及捲繞至吸收性芯體41之非肌膚對向面側之下方而被覆該吸收性芯體41之非肌膚對向面側之非肌膚側部分42b。又，包芯片材42於非肌膚側部分42b具有片材彼此之重疊部42c。 被覆吸收性芯體41之包芯片材既可由一片片材包覆吸收性芯體41之整體，亦可由兩片以上之片材包覆吸收性芯體41之整體。例如，吸收性芯體41之肌膚對向面側與非肌膚對向面側亦可由不同之片材被覆。無論用於吸收性芯體41之被覆之片材之片數，將被覆吸收性芯體41之肌膚對向面側之包芯片材亦稱作肌膚側包芯片材42a，將被覆吸收性芯體41之非肌膚對向面側之部分亦稱作非肌膚側包芯片材42b。 於第1實施形態之衛生棉1中，如圖2所示，包芯片材42中之被覆吸收性芯體41之肌膚對向面側之肌膚側部分(肌膚側包芯片材)42a之全域成為包含血球凝集劑之凝集劑配置部9。肌膚側包芯片材42a係於衛生棉1之厚度方向上配置於較正面片材2靠近背面片材3之位置之下方構件之一。衛生棉1具有肌膚側包芯片材42a、吸收性芯體41及非肌膚側包芯片材42b作為下方構件。包含血球凝集劑之凝集劑配置部9較佳為至少形成於作為在吸收性物品之厚度方向上與正面片材2鄰接之下方構件的肌膚側包芯片材42a。包含血球凝集劑之凝集劑配置部9可僅形成於肌膚側包芯片材42a，亦可形成於肌膚側包芯片材42a及吸收性芯體41，亦可以跨及肌膚側包芯片材42a、吸收性芯體41及非肌膚側包芯片材42b之方式形成。 於第1實施形態之衛生棉1中，肌膚側包芯片材42a之凝集劑配置部9係下方構件中之配置有血球凝集劑之範圍，於俯視衛生棉1時，凝集劑配置部9與防漏槽8中之全域重疊。然而，第1實施形態不限定於此，凝集劑配置部9亦可包含存在於排泄部對向部B之橫向中央側而不與側方防漏槽81、81重疊之部分、及與該等相隔而與側方防漏槽81、81重疊之部分而構成。 於第2實施形態之衛生棉1A中，如圖3及圖4所示，肌膚側包芯片材42a中之相互隔開之一對帶狀部分成為包含血球凝集劑之凝集劑配置部9A、9A。凝集劑配置部9A、9A於俯視衛生棉1時之隔著排泄位置部P之兩側各側分別沿縱向X延伸而形成。 於第2實施形態之衛生棉1A中，肌膚側包芯片材42a之凝集劑配置部9A、9A係下方構件中之配置有血球凝集劑之範圍，如圖3所示，於俯視衛生棉1時，凝集劑配置部9A、9A與防漏槽8中之沿縱向X延伸之一對側方防漏槽81、81重疊。關於第2實施形態之衛生棉1A，未特別說明之方面與第1實施形態之衛生棉1相同，可適當地應用對第1實施形態之說明。 第1實施形態之衛生棉1中之側方防漏槽81之全域與作為配置有血球凝集劑之範圍之凝集劑配置部9重疊，但於第2實施形態之衛生棉1A中，於衛生棉1A之橫向Y之中央部形成有未配置血球凝集劑之區域，防漏槽8亦可於前方防漏槽82及後方防漏槽83具有未與凝集劑配置部9A、9A重疊之部分。再者，於第1實施形態之衛生棉1及第2實施形態之衛生棉1A之任一者中，就於橫向Y上抑制經血自防漏槽之內側向外側移動，維持良好之防漏性能之觀點而言，均較佳為一對側方防漏槽81、81之中央圓弧狀部81b之縱向X之全長與凝集劑配置部9或9A重疊，且較佳為一對側方防漏槽81、81之縱向X之全長之50%以上且100%以下與凝集劑配置部9或9A重疊，進而較佳為70%以上且100%以下與凝集劑配置部9或9A重疊。 包芯片材係出於提高單獨時保形性不充分之吸收性芯體之保形性或防止吸收性芯體之構成材料之漏出之目的而使用者，使用薄紙或不織布等纖維片材。 作為構成薄紙之纖維素系纖維，可列舉木漿纖維、嫘縈纖維、棉纖維、乙酸纖維素纖維等。作為纖維素系纖維之原料紙漿，可列舉：針葉樹牛皮紙漿或闊葉樹牛皮紙漿之類之木漿、棉紙漿或草類紙漿等非木漿。該等纖維素系纖維可單獨使用1種或將2種以上組合而使用。又，就提高強度之觀點而言，亦可混合少量非纖維素系纖維。作為非纖維素系纖維，可列舉：聚乙烯、聚丙烯等聚烯烴系纖維、聚酯、聚醯胺等縮合系纖維等。薄紙之構成纖維中，纖維素系纖維之比例較佳為70質量%以上且100質量%以下，更佳為90質量%以上且100質量%以下，進而較佳為100質量%。 亦可使用不織布作為包芯片材。作為不織布之種類，可無特別限制地使用藉由各種製法所製成之不織布，例如可列舉：紡黏不織布、熔噴不織布、藉由高速水流處理使纖維網之構成纖維彼此交絡而獲得之不織布即水刺不織布、藉由熱風處理使纖維網之構成纖維彼此熱熔合而獲得之不織布即熱風不織布、利用接著劑使纖維網之構成纖維彼此接著而獲得之不織布即樹脂黏著不織布等。水刺不織布或熱風不織布、樹脂黏著不織布之纖維網可藉由梳棉機或於空氣中使纖維進行纖維堆積而成之氣紡法等而製造。 不織布之原料纖維可列舉：木漿纖維、嫘縈纖維、棉纖維、乙酸纖維素等纖維素系之親水性纖維、或包含聚乙烯、聚丙烯等聚烯烴、聚對苯二甲酸乙二酯等聚酯、尼龍等聚醯胺等合成樹脂之合成纖維。合成纖維亦可使用芯鞘型或並列型之複合纖維。該等中，基於與使用薄紙相同之理由，於各種製法之不織布之情形時，亦較佳為原料纖維為纖維素系纖維者。不織布之構成纖維中，纖維素系纖維之比例較佳為70質量%以上且100質量%以下，更佳為90質量%以上且100質量%以下，進而較佳為100質量%。不織布之原料纖維可單獨使用1種或將2種以上組合而使用。 本實施形態之衛生棉1之吸收性芯體41包含紙漿纖維與高吸收性聚合物之混合纖維堆積體。混合纖維堆積體係利用具備於周面具有集聚用凹部之纖維堆積滾筒的公知之滾筒式纖維堆積裝置所製造者，係一面自集聚用凹部之底面抽吸，一面將作為吸收性芯體之形成材料之紙漿纖維及高吸收性聚合物以飛散狀態供給至纖維堆積滾筒之周面，使吸收性芯體之形成材料堆積於集聚用凹部內後，自集聚用凹部進行脫模而獲得。本實施形態之衛生棉1之吸收性芯體41亦可為不含高吸收性聚合物之紙漿纖維之單獨纖維堆積體。 作為構成吸收性芯體41之紙漿纖維，可列舉木漿纖維、嫘縈纖維、棉纖維、乙酸纖維素等纖維素系之親水性纖維。該等纖維可單獨使用1種或將2種以上組合而使用。作為紙漿纖維之原料紙漿，可列舉：針葉樹牛皮紙漿或闊葉樹牛皮紙漿之類之木漿、棉紙漿或草類紙漿等非木漿。又，就提高強度之觀點而言，吸收性芯體41中除了包含纖維素系之親水性纖維之紙漿纖維以外，亦可混合少量聚乙烯、聚丙烯等聚烯烴系纖維、聚酯、聚醯胺等縮合系纖維等合成纖維。再者，本發明中之吸收性芯體之紙漿纖維(纖維素系纖維)、尤其是木漿纖維之比例較佳為70質量%以上且100質量%以下，更佳為90質量%以上且100質量%以下，進而較佳為100質量%。 又，吸收性芯體41中亦可含有高吸收性聚合物(吸水性聚合物)。作為高吸收性聚合物，通常使用粒子狀者，但亦可為纖維狀者。於使用粒子狀之高吸收性聚合物之情形時，其形狀可為球狀、塊狀、袋狀或不定形狀中之任一者。作為高吸收性聚合物，通常可使用丙烯酸或丙烯酸鹼金屬鹽之聚合物或共聚物。作為其例，可列舉聚丙烯酸及其鹽、以及聚甲基丙烯酸及其鹽。作為聚丙烯酸鹽或聚甲基丙烯酸鹽，可較佳地使用鈉鹽。又，亦可使用使丙烯酸或甲基丙烯酸與馬來酸、伊康酸、丙烯醯胺、2-丙烯醯胺-2-甲基丙磺酸、2-(甲基)丙烯醯基乙磺酸、(甲基)丙烯酸2-羥基乙酯或苯乙烯磺酸等共聚單體於不使高吸收性聚合物之性能降低之範圍內進行共聚而成之共聚物。藉由含有吸水性聚合物，可更穩定地快速吸收大量之血液等排泄液並加以保持。 又，視需要亦可於吸收性芯體41中調配除臭劑或抗菌劑等。 作為使包芯片材42等衛生棉之構成構件含有血球凝集劑而形成凝集劑配置部之方法，並無特別限制，例如，使包含陽離子性聚合物之血球凝集劑溶解於水、乙醇、及該等之混合液等適當之溶劑中而製成溶液，使其附著於構成構件之所期望之部位後，進行乾燥而將溶劑去除之方法就使血球凝集劑於凝集劑配置部中均勻地配置之方面而言較佳。作為使溶液附著於構成構件之方法，可採用向構成構件之特定部位滴加溶液、各種塗敷方法。例如可列舉噴霧法、浸漬法、轉印法、模嘴塗敷、凹版塗敷、噴墨法、網版印刷等使用公知之液體塗敷裝置向構成構件之特定部位塗敷液體等。又，乾燥可為藉由加熱進行之乾燥、藉由減壓進行之乾燥、組合加熱與減壓之乾燥之任一者，但亦可取代該等強制乾燥而為自然乾燥。 第1及第2實施形態之衛生棉1、1A與通常之經期衛生棉同樣地固定於短褲之褲襠部等而使用。 根據第1實施形態之衛生棉1及第2實施形態之衛生棉1A，即便於因穿著中施加之外力而於防漏槽8產生正面片材2與吸收體4之剝離之情形時，亦如圖5所示，肌膚側包芯片材42a等下方構件中含有之血球凝集劑作用於進入正面片材2與吸收體4之間之間隙之經血11，而於該間隙內或其附近之吸收體4內生成紅血球之凝集塊16，藉此可抑制經血11越過防漏槽8而擴散。藉此可防止產生側漏等洩漏。 又，於將正面片材2與吸收體4一體地加壓壓縮而形成之防漏槽8中產生吸收體4之厚度方向上之間隙之情形時，亦同樣地，肌膚側包芯片材42a等下方構件中含有之血球凝集劑作用於進入吸收體4之間隙之經血11，而於該間隙內或其附近之吸收體4內生成紅血球之凝集塊16，藉此可抑制經血11越過防漏槽8而擴散。藉此可防止產生側漏等洩漏。 就藉由生成紅血球之凝集塊16而有效地抑制經血經由防漏槽8中產生之正面片材2與吸收體4之間隙而擴散之觀點而言，肌膚側包芯片材42a等下方構件之凝集劑配置部9或9A較佳為滿足以下之條件(1)～(3)中之任一者以上。 (1)凝集劑配置部9或9A之與防漏槽8之沿縱向X延伸之部分(側方防漏槽81)重疊之重複部分中之血球凝集劑之每單位面積之存在量為6 g/m2
以上且80 g/m2
以下，更佳為12 g/m2
以上且70 g/m2
以下。 所謂此處言及之血球凝集劑之量，於血球凝集劑為陽離子性聚合物之情形時，係指該陽離子性聚合物之純分量，血球凝集劑之每單位面積之量係以如下方式進行測定。 [測定方法] 於配置使陽離子性聚合物溶解而成之溶液後，於30℃10%RH之條件下靜置24小時而使其乾燥，將凝集劑配置部切出，測定其面積，比較凝集劑配置前後之重量，藉此算出乾燥後所含有之每單位面積之血球凝集劑之存在量。 (2)凝集劑配置部9或9A之與防漏槽8之沿縱向X延伸之部分(側方防漏槽81)重疊之重複部分中之血球凝集劑之每單位面積之存在量多於凝集劑配置部9或9A中之不與防漏槽8重疊之部分之血球凝集劑之每單位面積之存在量。藉由使重複部分集中地含有較多之血球凝集劑，可抑制所使用之血球凝集劑之總量，並且可有效地提高紅血球之凝集塊16之生成能力及利用其之防漏效果。 (3)用作血球凝集劑之陽離子性聚合物之分子量較佳為2000以上，進而較佳為1萬以上，進而更佳為15萬以上。分子量之上限值較佳為3000萬以下，進而較佳為2200萬以下，進而更佳為1000萬以下。又，較佳為2000以上且3000萬以下，進而較佳為1萬以上且2200萬以下，進而更佳為15萬以上且1000萬以下。 又，衛生棉1、1A之正面片材2較佳為其整體為親水性，且較佳為至少與凝集劑配置部9、9A及防漏槽8、尤其是側方防漏槽81重疊之部位為親水性。若正面片材2為親水性，則親水性之經血於吸收體內擴散時，於與凝集劑配置部9A之一部分或整體重疊之側方防漏槽81中亦可高效率地擴散。 作為使正面片材2之整體或一部分為親水性之方法，可列舉如下方法：使用以木漿纖維、嫘縈纖維、棉纖維、乙酸纖維素纖維等纖維素系纖維為主要構成纖維之不織布、或以利用親水性油劑使聚乙烯、聚丙烯等聚烯烴系纖維、聚酯、聚醯胺等縮合系纖維等合成纖維親水化而成之纖維為主要構成纖維之不織布等作為正面片材2。 第1實施形態之衛生棉1及第2實施形態之衛生棉1A中，如上所述，防漏槽8、更具體而言為防漏槽8中之一對側方防漏槽81於隔著排泄位置部P而位於橫向Y之兩側之部分具有具朝橫向Y之外側凸狀地彎曲之俯視形狀的中央圓弧狀部81b。本發明之吸收性物品中之防漏槽8或一對側方防漏槽81於隔著排泄位置部P之兩側具有朝外側凸狀地彎曲之形狀之圓弧狀部81b時，於在穿著中自橫向Y之左右向衛生棉之側翼部中央施加外力時會促使衛生棉向穿著者之肌膚側隆起，故而外力分散，施加於側方防漏槽81之外力降低。其結果，側方防漏槽81部中之正面片材自吸收體之剝離、或吸收體之加壓壓縮部中產生之間隙之程度及產生頻度降低。因此具有利用防漏槽進行之液體之移動阻止、吸收性物品之防漏性能進一步提高等優點，故而較佳。又，於如第1實施形態及第2實施形態般血球凝集劑亦配置於較側方防漏槽81更靠橫向內側之情形時，於經血到達側方防漏槽之前，經血容易與血球凝集劑接觸而分離為凝集塊與血漿成分。因此，與側方防漏槽81、81具有朝橫向Y之外側凸狀地彎曲之形狀，具有該形狀之側方防漏槽81、81夾著排泄位置部P這一點相配合而使血漿成分容易沿側方防漏槽81、81於縱向X上擴散，難以產生側漏。又，於穿著初期產生之排泄位置部P及其周邊之凝集塊會抑制繼續排泄之經血向橫向Y之外側擴散，可與側方防漏槽81作為雙重防漏機構發揮功能，故而亦對長時間穿著時抑制經血之側漏有效。 繼而，對作為本發明之吸收性物品之第3及第4實施形態之經期衛生棉進行說明。於第3及第4實施形態之經期衛生棉中，一對側方防漏槽81與同第1實施形態之衛生棉1一樣之凝集劑配置部9、即以跨及肌膚側包芯片材42a之吸收性芯體之重疊之部分之全域之方式而形成之凝集劑配置部重疊，或者與同第2實施形態之衛生棉1A一樣之凝集劑配置部9A、9A、即局部地形成於肌膚側包芯片材42a之與吸收性芯體重疊之部分之凝集劑配置部9A、9A重疊。關於第3及第4實施形態之經期衛生棉，對與第1或第2實施形態之衛生棉1不同之方面進行說明，對於相同之方面，標註相同之符號而省略說明。關於未特別說明之方面，可適當地應用對第1或第2實施形態之衛生棉之說明。 圖6係表示本發明之第3實施形態之經期衛生棉之俯視圖。於第3實施形態之經期衛生棉1B(以下，亦稱作衛生棉1B)中，於排泄部對向部B中，側方防漏槽81具有朝橫向Y之內側凸狀地彎曲之圓弧狀部(內凸彎曲部)。具體而言，如圖6所示，衛生棉1B中之一對側方防漏槽81之排泄部對向部B、較佳為隔著排泄位置部P而位於橫向Y之兩側之部分成為具有朝橫向Y之外側凹狀地彎曲之俯視形狀之圓弧狀部(內凸彎曲部)81d。本發明之吸收性物品中之防漏槽8或一對側方防漏槽81於隔著排泄位置部P之兩側具有朝外側凹狀地彎曲之形狀之圓弧狀部81d時，於在穿著中自橫向Y之左右向衛生棉之側翼部中央施加外力時外力會向衛生棉之X方向之前部方向及後部方向分散，故而施加於側方防漏槽81之外力降低。其結果，側方防漏槽81部中之正面片材自吸收體之剝離、或吸收體之加壓壓縮部中產生之間隙之程度及產生頻度降低。因此，防漏槽以此方式具有上述內凸彎曲部時，具有利用防漏槽進行之液體之移動阻止、吸收性物品之防漏性能進一步提高等優點，故而較佳。 又，由於側方防漏槽81、81朝排泄位置部P凸狀地彎曲，故而，於短時間內排出大量經血之情形時，經血容易順著防漏槽沿縱向X擴散，經血容易與血球凝集劑接觸而於側方防漏槽81之附近區域形成凝集塊並分離為血漿成分，尤其，血漿成分容易向縱向X擴散。又，於排泄部對向部B中，較側方防漏槽81更靠橫向Y外側之可吸收面積較廣。因此，即便於短時間內排出大量經血時，亦難以產生來自橫向之經血洩漏。 圖7係表示本發明之第4實施形態之經期衛生棉之俯視圖。第4實施形態之經期衛生棉1C(以下，亦稱作衛生棉1C)與衛生棉1、1A同樣地，側方防漏槽81於橫向Y上之隔著排泄位置部P之兩側分別朝外側具有具凸狀之俯視形狀之圓弧狀部81b，進而，於該圓弧狀部81b、81b各者之橫向Y之外側具有第2防漏槽85。第2防漏槽85與側方防漏槽81之中央圓弧狀部81b同樣地具有朝橫向Y之外側凸狀地彎曲之俯視形狀，中央圓弧狀部81b與第2防漏槽85於橫向Y上排列而形成，且相互大致平行地形成。中央圓弧狀部81b及位於其外側之第2防漏槽85可與跨及兩者間而連續之凝集劑配置部9或9A重疊，亦可與於橫向Y上隔開間隙而形成之分開之凝集劑配置部重疊。若於隔著排泄位置部P之兩側分別具有與凝集劑配置部重疊之雙重防漏槽，則於自橫向Y之左右向衛生棉之側翼部中央施加外力時，藉由雙重防漏槽而進一步促使衛生棉向穿著者之肌膚側隆起，故而外力分散，施加於側方防漏槽81之外力降低。其結果，側方防漏槽81部中之正面片材自吸收體之剝離、或吸收體之加壓壓縮部中產生之間隙之程度及產生頻度降低。因此具有利用防漏槽進行之液體之移動阻止、吸收性物品之防漏性能進一步提高等優點，故而較佳。 圖8係表示本發明之第5實施形態之經期衛生棉之俯視圖。第5實施形態之經期衛生棉1D(以下，衛生棉1D)與衛生棉1、1A同樣地，防漏槽8中之一對側方防漏槽81於隔著排泄位置部P而位於橫向Y之兩側之部分分別形成有沿縱向X直線狀地延伸之一對側方防漏槽81。一對側方防漏槽81與同第1實施形態之衛生棉1一樣之凝集劑配置部9、即以跨及肌膚側包芯片材42a之吸收性芯體之重疊之部分之全域之方式而形成之凝集劑配置部重疊，或者與同第2實施形態之衛生棉1A一樣之凝集劑配置部9A、9A、即局部地形成於肌膚側包芯片材42a之與吸收性芯體重疊之部分之凝集劑配置部9A、9A重疊。於圖8所示之衛生棉1D中，以符號89表示防漏槽8中之與凝集劑配置部重疊之區域。於血球凝集劑亦配置於較側方防漏槽81更靠橫向內側之情形時，於經血到達側方防漏槽之前，經血容易與血球凝集劑接觸而分離為凝集塊與血漿成分，達到側方防漏槽之血漿成分沿直線狀之側方防漏槽81快速地於縱向X上擴散，藉此，吸收量進一步提高。 用於本發明之血球凝集性纖維之血球凝集劑係使用具有可使血液中之紅血球凝集之作用者。藉由血球凝集劑而凝集之紅血球成為凝集塊。作為血球凝集劑，較佳為以使血液中之紅血球凝集而形成凝集塊並與血漿成分分離之方式發揮作用者。作為血球凝集劑，陽離子性聚合物係有用。其理由如下。紅血球於其表面具有紅血球膜。紅血球膜具有2層結構。該2層結構包含作為下層之紅血球膜骨架、及作為上層之脂質皮膜。露出於紅血球之表面之脂質皮膜中包含被稱作血型糖蛋白(glycophorin)之蛋白質。血型糖蛋白於其末端具有鍵結有帶有被稱作唾液酸之陰離子電荷之糖的糖鏈。其結果，紅血球可作為帶有陰離子電荷之膠體粒子而進行處理。對於膠體粒子之凝集，通常使用凝集劑。若考慮紅血球為陰離子性之膠體粒子，則使用陽離子性之物質作為凝集劑就中和紅血球之電雙層之方面而言有利。又，若凝集劑具有高分子鏈，則容易產生吸附於紅血球之表面之凝集劑之高分子鏈彼此的纏結，由此促進紅血球之凝集。進而，於凝集劑具有官能基之情形時，藉由該官能基間之相互作用而亦促進紅血球之凝集，故而較佳。藉由血球凝集劑(陽離子性聚合物)，可藉由以上之作用機制於經血中生成紅血球之凝集塊。 本發明中所使用之較佳之血球凝集劑尤佳為具有如下性質者：於向模擬血液中添加有1000 ppm測定樣品劑時，於維持血液之流動性之狀態下，至少2個以上之紅血球凝集而形成凝集塊。 上述之「維持血液之流動性之狀態」意指如下狀態：於將添加有1000 ppm測定樣品劑之模擬血液10 g加入螺旋口瓶(Maruemu公司製造 編號「螺旋口管No.4」、口內徑14.5 mm、主體直徑27 mm、全長55 mm)中，並將加入有該模擬血液之螺旋口瓶反轉180度時，於5秒內80%以上之該模擬血液流下。所謂模擬血液，係指以使用B型黏度計(東機產業股份有限公司製造 型號TVB-10M、測定條件：轉子No.19、30 rpm、25℃、60秒)所測得之黏度成為8 mPa・s之方式製備脫纖維馬血(Nippon Biotest Laboratories股份有限公司製造)之血球、血漿比率而成者。 上述之「2個以上之紅血球凝集而形成凝集塊」與否係以如下方式進行判斷。即，利用生理鹽水將添加有1000 ppm測定樣品劑之上述模擬血液稀釋至4000倍，藉由使用雷射繞射/散射式粒度分佈測定裝置(HORIBA公司製造 型號：LA-950V2、測定條件：流槽測定、循環速度1、無超音波)之雷射繞射散射法，於在溫度25℃下所測得之體積粒徑平均之中值粒徑為10 μm以上之情形時，判斷：「2個以上之紅血球凝集而形成凝集塊」。 本發明中所使用之血球凝集劑係符合上述性質之單一化合物或符合上述性質之單一化合物複數種組合、或者藉由複數種化合物之組合而滿足上述性質之(可表現出紅血球之凝集)劑。即，所謂血球凝集劑，終歸係指限定於根據上述定義之具有紅血球凝集作用者之劑。因此，於血球凝集劑中包含不符合上述定義之第三成分之情形時，將其表達為血球凝集劑組合物而與血球凝集劑進行區別。 作為本發明中所使用之血球凝集劑，可列舉包含陽離子性聚合物者作為較佳者。作為陽離子性聚合物，例如可列舉陽離子化纖維素、或羥丙基三甲基氯化銨澱粉等陽離子化澱粉等。又，本發明中所使用之血球凝集劑亦可包含四級銨鹽均聚物、四級銨鹽共聚物或四級銨鹽縮聚物作為陽離子性聚合物。於本發明中，所謂「四級銨鹽」，包含於氮原子之位置具有正一價之電荷之化合物、或藉由中和於氮原子之位置產生正一價之電荷之化合物，作為其具體例，可列舉四級銨陽離子之鹽、三級胺之中和鹽、及於水溶液中帶有陽離子之三級胺。以下所述之「四級銨部位」亦以同樣之含義而使用，係於水中帶正電之部位。又，於本發明中，所謂「共聚物」，係指藉由2種以上之聚合性單體之共聚而獲得之聚合物，包含二元共聚物及三元以上之共聚物兩者。於本發明中，所謂「縮聚物」，係指藉由使包含2種以上之單體之縮合物進行聚合而獲得之縮聚物。 於本發明中所使用之血球凝集劑包含四級銨鹽均聚物及/或四級銨鹽共聚物及/或四級銨鹽縮聚物作為陽離子性聚合物之情形時，該血球凝集劑可包含四級銨鹽均聚物、四級銨鹽共聚物及四級銨鹽縮聚物中之任一種，或者，亦可包含任意2種以上之組合。又，四級銨鹽均聚物可單獨使用1種或將2種以上組合而使用。同樣地，四級銨鹽共聚物可單獨使用1種或將2種以上組合而使用。進而同樣地，四級銨鹽縮聚物可單獨使用1種或將2種以上組合而使用。再者，於本說明書中，所謂「血球凝集劑」，係指可使血液之紅血球凝集之單一化合物或該單一化合物之複數種組合、或者藉由複數種化合物之組合而表現出紅血球之凝集之劑。即，所謂血球凝集劑，終歸係指限定於具有紅血球凝集作用者之劑。因此，於血球凝集劑中包含第三成分之情形時，將其表達為血球凝集劑組合物而與血球凝集劑進行區別。再者，所謂此處言及之「單一化合物」，係包含具有相同之組成式，但因重複單元數不同而分子量不同之化合物之概念。 上述各種陽離子性聚合物中，尤其，使用四級銨鹽均聚物、四級銨鹽共聚物或四級銨鹽縮聚物就對紅血球之吸附性之方面而言較佳。於以下之說明中，出於方便考慮，將四級銨鹽均聚物、四級銨鹽共聚物及四級銨鹽縮聚物總稱而稱作「四級銨鹽聚合物」。 四級銨鹽均聚物係藉由如下方式而獲得者：使用1種具有四級銨部位之聚合性單體，使其進行聚合。另一方面，四級銨鹽共聚物係藉由如下方式而獲得者：使用至少1種具有四級銨部位之聚合性單體，且視需要使用至少1種不具有四級銨部位之聚合性單體，使其等進行共聚。即，四級銨鹽共聚物係使用2種以上之具有四級銨部位之聚合性單體而使其等進行共聚而獲得者、或使用1種以上之具有四級銨部位之聚合性單體及1種以上之不具有四級銨部位之聚合性單體而使其等進行共聚而獲得者。四級銨鹽共聚物可為無規共聚物，可為交替共聚物，可為嵌段共聚物，或者，亦可為接枝共聚物。四級銨鹽縮聚物係藉由如下方式而獲得者：使用包含1種以上之具有四級銨部位之單體之縮合物，使該等縮合物進行聚合。即，四級銨鹽縮聚物係使用2種以上之具有四級銨部位之單體之縮合物而使其進行聚合而獲得者、或使用包含1種以上之具有四級銨部位之單體及1種以上之不具有四級銨部位之單體之縮合物而使其進行縮聚而獲得者。 四級銨鹽聚合物係具有四級銨部位之陽離子性之聚合物。四級銨部位可藉由使用烷基化劑之三級胺之四級銨化而生成。或者，可使三級胺溶解於酸或水中而藉由中和而生成。或者，可藉由利用包括縮合反應之親核反應而進行之四級銨化而生成。作為烷基化劑，例如可列舉鹵化烷基、或硫酸二甲酯及硫酸二甲酯等硫酸二烷基酯。該等烷基化劑中，若使用硫酸二烷基酯，則不會產生於使用鹵化烷基之情形時可能產生之腐蝕之問題，故而較佳。作為酸，例如可列舉鹽酸、硫酸、硝酸、乙酸、檸檬酸、磷酸、氟磺酸、硼酸、鉻酸、乳酸、草酸、酒石酸、葡萄糖酸、甲酸、抗壞血酸、玻尿酸等。尤其，若使用利用烷基化劑使三級胺部位四級銨化而成之四級銨鹽聚合物，則可確實地中和紅血球之電雙層，故而較佳。利用包括縮合反應之親核反應而進行之四級銨化可如二甲基胺與表氯醇之開環縮聚反應、雙氰胺與二伸乙基三胺之環化反應般發生。 如上所述，就有效地生成紅血球之凝集塊之觀點而言，用作血球凝集劑之陽離子性聚合物之分子量較佳為2000以上，進而較佳為1萬以上，進而更佳為3萬以上，進而更佳為15萬以上。藉由陽離子性聚合物之分子量為該等值以上，而充分地產生紅血球間之陽離子性聚合物彼此之纏結、或紅血球間之陽離子性聚合物之交聯，經血有效地生成紅血球之凝集塊，抑制血液之擴散之效果提高，故而更佳。分子量之上限值較佳為3000萬以下，進而較佳為2200萬以下，進而更佳為1000萬以下。藉由陽離子性聚合物之分子量為該等值以下，而陽離子性聚合物良好地溶解於經血中。就經血分離為紅血球與血漿，有效地生成紅血球之凝集塊，血漿被高吸收聚合物高效率地吸收，吸收量與吸收速度提高，並且經血自防漏槽之內側向外側之移動得到抑制，維持良好之防漏性能之觀點而言，陽離子性聚合物之分子量較佳為2000以上且3000萬以下，進而較佳為1萬以上且2200萬以下，進而更佳為15萬以上且1000萬以下。再者，若陽離子性聚合物之分子量為1萬以上且15萬以下、尤其是1萬以上且12萬以下，則經血之凝集塊不會過度肥大化而生成為適當之大小，故而凝集塊不會堵塞吸收性芯體中所包含之紙漿纖維空隙或包芯片材之孔隙部內之空隙，於陽離子性聚合物良好地溶解於經血中之後，亦可較高程度地維持吸收性芯體及包芯片材中之經血之透過性，就該方面而言較佳。 陽離子性聚合物之分子量可藉由適當地選擇其聚合條件而進行控制。又，亦可於上述分子量範圍內組合2種以上之分子量不同之陽離子性聚合物。陽離子性聚合物之分子量可使用Tosoh股份有限公司製造之HLC-8320GPC進行測定。具體之測定條件如下。再者，所謂本發明中言及之分子量，係指重量平均分子量。 作為管柱，以管柱溫度：40℃使用將Tosoh股份有限公司製造之保護管柱α與分析管柱α-M串聯連接而成者。檢測器係使用RI(Refractive Index，折射率)。作為測定樣品，使1 mg之測定對象之處理劑(四級銨鹽聚合物)對溶析液1 mL溶解。包含甲基丙烯酸羥基乙酯等水溶性聚合性單體之共聚物係使用使150 mmol/L之硫酸鈉與1質量%之乙酸溶解於水中而成之溶析液。包含甲基丙烯酸羥基乙酯等水溶性聚合性單體之共聚物係使用使分子量5900之支鏈澱粉、分子量47300之支鏈澱粉、分子量21.2萬之支鏈澱粉、分子量78.8萬之支鏈澱粉各2.5 mg對溶析液10 mL溶解而成之支鏈澱粉混合物作為分子量標準。包含甲基丙烯酸羥基乙酯等水溶性聚合性單體之共聚物係以流速：1.0 mL/min、注入量：100 μL進行測定。除包含甲基丙烯酸羥基乙酯等水溶性聚合性單體之共聚物以外，使用使50 mmol/L之溴化鋰與1質量%之乙酸溶解於乙醇：水＝3：7(體積比)中而成之溶析液。除包含甲基丙烯酸羥基乙酯等水溶性聚合性單體之共聚物以外，使用使分子量106之聚乙二醇(PEG)、分子量400之PEG、分子量1470之PEG、分子量6450之PEG、分子量5萬之聚環氧乙烷(PEO)、分子量23.5萬之PEO、分子量87.5萬之PEO各10 mg對溶析液20 mL溶解而成之PEG-PEO混合物作為分子量標準。除包含甲基丙烯酸羥基乙酯等水溶性聚合性單體之共聚物以外，以流速：0.6 mL/min、注入量：100 μL進行測定。 就有效地生成紅血球之凝集塊之觀點而言，陽離子性聚合物較佳為水溶性。於本發明中，所謂「水溶性」，係指如下性質：於100 mL之玻璃燒杯(5 mmΦ)中將0.05 g之1 mm以下之粉末狀或厚度0.5 mm以下之膜狀陽離子性聚合物添加混合於25℃之50 mL離子交換水中時，放入長度20 mm、寬度7 mm之攪拌棒，於使用AS ONE股份有限公司製造之磁攪拌器HPS-100之600 rpm攪拌下，其全部量於24小時內溶解於水中。再者，於本發明中，作為進而較佳之溶解性，較佳為全部量於3小時內溶解於水中，進而較佳為全部量於30分鐘內溶解於水中。 陽離子性聚合物較佳為具有主鏈、及鍵結於其之複數條側鏈之結構者。尤其，四級銨鹽聚合物較佳為具有主鏈、及鍵結於其之複數條側鏈之結構者。四級銨部位較佳為存在於側鏈。於該情形時，若主鏈與側鏈以1點鍵結，則側鏈之可撓性難以受阻，存在於側鏈之四級銨部位順利地吸附於紅血球之表面。當然，於本發明中，陽離子性聚合物之主鏈與側鏈可以2點或2點以上鍵結。於本發明中，所謂「以1點鍵結」，係指構成主鏈之碳原子中之1個與位於側鏈之末端之1個碳原子單鍵結。所謂「以2點以上鍵結」，係指構成主鏈之碳原子中之2個以上分別與位於側鏈之末端之2個以上之碳原子單鍵結。 於陽離子性聚合物為具有主鏈、及鍵結於其之複數條側鏈之結構者之情形、例如四級銨鹽聚合物為具有主鏈、及鍵結於其之複數條側鏈之結構者之情形時，各側鏈之碳數較佳為4以上，進而較佳為5以上，進而更佳為6以上。碳數之上限值較佳為10以下，進而較佳為9以下，進而更佳為8以下。例如，側鏈之碳數較佳為4以上且10以下，進而較佳為5以上且9以下，進而更佳為6以上且8以下。所謂側鏈之碳數，係指該側鏈中之四級銨部位(陽離子部位)之碳數，即便作為抗衡離子之陰離子中包含碳，其碳亦不包含於計數。尤其，自側鏈之碳原子中鍵結於主鏈之碳原子至鍵結於四級氮之碳原子為止之碳數為上述範圍時，四級銨鹽聚合物吸附於紅血球之表面時之位阻性降低，故而較佳。 於四級銨鹽聚合物為四級銨鹽均聚物之情形時，作為該均聚物，例如可列舉具有四級銨部位或三級胺部位之乙烯基系單體之聚合物。於使具有三級胺部位之乙烯基系單體進行聚合之情形時，成為於聚合前及/或聚合後利用烷基化劑使三級胺部位四級銨化而成之四級銨鹽均聚物，或者成為於聚合前及/或聚合後利用酸對三級胺部位進行中和而成之三級胺中和鹽，或者成為於聚合後於水溶液中帶有陽離子之三級胺。烷基化劑或酸之例如上所述。 尤其，四級銨鹽均聚物較佳為具有下式1所表示之重複單元。 [化1]作為四級銨鹽均聚物之具體例，可列舉聚乙烯亞胺等。又，可列舉：作為具有四級銨部位之側鏈與主鏈以1點鍵結者之聚(2-甲基丙烯醯氧基乙基二甲基胺四級鹽)、聚(2-甲基丙烯醯氧基乙基三甲基銨鹽)、聚(2-甲基丙烯醯氧基乙基二甲基乙基銨甲基硫酸鹽)、聚(2-丙烯醯氧基乙基二甲基胺四級鹽)、聚(2-丙烯醯氧基乙基三甲基胺四級鹽)、聚(2-丙烯醯氧基乙基二甲基乙基銨乙基硫酸鹽)、聚(3-二甲胺基丙基丙烯醯胺四級鹽)、聚甲基丙烯酸二甲胺基乙酯、聚烯丙基胺鹽酸鹽、陽離子化纖維素、聚乙烯亞胺、聚二甲胺基丙基丙烯醯胺、聚脒等。另一方面，作為具有四級銨部位之側鏈與主鏈以2點以上鍵結之均聚物之例，可列舉聚二烯丙基二甲基氯化銨、聚二烯丙基胺鹽酸鹽。 於四級銨鹽聚合物為四級銨鹽共聚物之情形時，作為該共聚物，可使用2種以上之用於上述四級銨鹽均聚物之聚合之聚合性單體進行共聚而獲得之共聚物。或者，作為四級銨鹽共聚物，可使用1種以上之用於上述四級銨鹽均聚物之聚合之聚合性單體與1種以上之不具有四級銨部位之聚合性單體進行共聚而獲得之共聚物。進而，亦可除乙烯基系聚合性單體以外或取代其而使用其他聚合性單體、例如-SO2
-等。四級銨鹽共聚物如上所述可為二元共聚物或三元以上共聚物。 尤其，就有效地生成紅血球之凝集塊之觀點而言，四級銨鹽共聚物較佳為具有上述式1所表示之重複單元、及下式2所表示之重複單元。 [化2]又，作為不具有四級銨部位之聚合性單體，可使用陽離子性聚合性單體、陰離子性聚合性單體、或非離子性聚合性單體。該等聚合性單體中，尤其，藉由使用陽離子性聚合性單體或非離子性聚合性單體，而於四級銨鹽共聚物內不會發生與四級銨部位之電荷相抵，故而可有效地產生紅血球之凝集。關於陽離子性聚合性單體之例，作為具有於特定之條件下帶有陽離子之氮原子之環狀化合物，可列舉乙烯基吡啶等，作為於主鏈具有於特定之條件下帶有陽離子之氮原子之直鏈狀化合物，可列舉雙氰胺與二伸乙基三胺之縮合化合物等。作為陰離子性聚合性單體之例，可列舉2-丙烯醯胺-2-甲基丙磺酸、甲基丙烯酸、丙烯酸及苯乙烯磺酸、以及該等化合物之鹽等。另一方面，作為非離子性聚合性單體之例，可列舉乙烯醇、丙烯醯胺、二甲基丙烯醯胺、乙二醇單甲基丙烯酸酯、乙二醇單丙烯酸酯、甲基丙烯酸羥基乙酯、丙烯酸羥基乙酯、甲基丙烯酸甲酯、丙烯酸甲酯、甲基丙烯酸乙酯、丙烯酸乙酯、甲基丙烯酸丙酯、丙烯酸丙酯、甲基丙烯酸丁酯、丙烯酸丁酯等。該等陽離子性聚合性單體、陰離子性聚合性單體、或非離子性聚合性單體可使用其等中之一者，或者，亦可將任意2種以上組合而使用。又，可將2種以上陽離子性聚合性單體組合而使用，可將2種以上陰離子性聚合性單體組合而使用，或者，亦可將2種以上非離子性聚合性單體組合而使用。使用陽離子性聚合性單體、陰離子性聚合性單體及/或非離子性聚合性單體作為聚合性單體而進行共聚而成之四級銨鹽共聚物之分子量如上所述較佳為1000萬以下，尤其較佳為500萬以下、特別是300萬以下(關於以下所例示之四級銨鹽共聚物，亦相同)。 作為不具有四級銨部位之聚合性單體，亦可使用具有可進行氫鍵結之官能基之聚合性單體。藉由將此種聚合性單體用於共聚，而於使用由此獲得之四級銨鹽共聚物使紅血球凝集時，容易生成較硬之凝集塊，高吸收性聚合物之吸收性能更難以受阻。作為可進行氫鍵結之官能基，例如可列舉-OH、-NH2
、-CHO、-COOH、-HF、-SH等。作為具有可進行氫鍵結之官能基之聚合性單體之例，可列舉甲基丙烯酸羥基乙酯、乙烯醇、丙烯醯胺、二甲基丙烯醯胺、乙二醇單甲基丙烯酸酯、乙二醇單丙烯酸酯、甲基丙烯酸羥基乙酯、丙烯酸羥基乙酯等。尤其，氫鍵較強地發揮作用之甲基丙烯酸羥基乙酯、甲基丙烯酸2-羥基乙酯、丙烯酸羥基乙酯、二甲基丙烯醯胺等由於四級銨鹽聚合物向紅血球之吸附狀態穩定化而較佳。該等聚合性單體可單獨使用1種或將2種以上組合而使用。 作為不具有四級銨部位之聚合性單體，亦可使用具有可進行疏水性相互作用之官能基之聚合性單體。藉由將此種聚合性單體用於共聚，而可實現上述之與使用具有可進行氫鍵結之官能基之聚合性單體之情形時相同之有利效果、即容易生成紅血球之較硬之凝集塊之效果。作為可進行疏水性相互作用之官能基，例如可列舉甲基、乙基、丁基等烷基、苯基、烷基萘基、氟化烷基等。作為具有可進行疏水性相互作用之官能基之聚合性單體之例，可列舉甲基丙烯酸甲酯、丙烯酸甲酯、甲基丙烯酸乙酯、丙烯酸乙酯、甲基丙烯酸丙酯、丙烯酸丙酯、甲基丙烯酸丁酯、丙烯酸丁酯、苯乙烯等。尤其，較強地發揮疏水性相互作用且不會使四級銨鹽聚合物之溶解性大幅降低之甲基丙烯酸甲酯、丙烯酸甲酯、甲基丙烯酸丁酯、丙烯酸丁酯等由於四級銨鹽聚合物向紅血球之吸附狀態穩定化而較佳。該等聚合性單體可單獨使用1種或將2種以上組合而使用。 四級銨鹽共聚物中之具有四級銨部位之聚合性單體與不具有四級銨部位之聚合性單體之莫耳比較佳為適當地進行調整以使紅血球藉由該四級銨鹽共聚物而充分地凝集。尤其，四級銨鹽共聚物中之具有四級銨部位之聚合性單體之莫耳比較佳為10莫耳%以上，進而較佳為22莫耳%以上，進而更佳為32莫耳%以上，進而更佳為38莫耳%以上。又，較佳為100莫耳%以下，進而較佳為80莫耳%以下，進而更佳為65莫耳%以下，進而更佳為56莫耳%以下。具體而言，具有四級銨部位之聚合性單體之莫耳比較佳為10莫耳%以上且100莫耳%以下，進而較佳為22莫耳%以上且80莫耳%以下，進而更佳為32莫耳%以上且65莫耳%以下，進而更佳為38莫耳%以上且56莫耳%以下。 於四級銨鹽聚合物為四級銨鹽縮聚物之情形時，作為該縮聚物，可使用藉由如下方式而獲得之縮聚物：使用上述包含1種以上之具有四級銨部位之單體之縮合物，使該等縮合物進行聚合。作為具體例，可列舉雙氰胺/二伸乙基三胺縮聚物、二甲基胺/表氯醇縮聚物等。 上述四級銨鹽均聚物及四級銨鹽共聚物可藉由乙烯基系聚合性單體之均聚法或共聚法而獲得。作為聚合方法，例如可利用自由基聚合、活性自由基聚合、活性陽離子聚合、活性陰離子聚合、配位聚合、開環聚合、縮聚等。聚合條件並無特別限制，只要適當地選擇可獲得具有目標之分子量、流動電位、及/或IOB(Inorganic Organic Balance，無機性與有機性平衡)值之四級銨鹽聚合物之條件即可。 以上所詳細說明之陽離子性聚合物係上述之「尤佳之血球凝集劑」之例示，其效果可參照日本專利特願2015-239286號、及作為該申請案之日本公開公報之日本專利特開2016-107100號公報及以該申請案為優先權主張之基礎的國際申請案之國際公開2016/093233號公報中所記載之實施例1至45。 又，本發明中所使用之血球凝集劑亦可為除聚陽離子(陽離子性聚合物)以外亦包含有1種以上之第三成分、例如溶劑、塑化劑、香料、抗菌/除臭劑、護膚劑等其他成分之組合物(血球凝集劑組合物)之形態。作為溶劑，可使用水、碳數1至4之飽和脂肪族一元醇等水溶性有機溶劑、或該水溶性有機溶劑與水之混合溶劑等。作為塑化劑，可使用甘油、聚乙二醇、丙二醇、乙二醇、1,3-丁二醇等。作為香料，可使用日本專利第4776407號公報中所記載之具有綠色草藥(green herbal)味香氣之香料、植物之萃取物、柑橘類之萃取物等。作為抗菌/除臭劑，可使用日本專利第4526271號公報中所記載之包含具有抗菌性之金屬之鈣霞石狀礦物、日本專利第4587928號公報中所記載之由具有苯基之聚合性單體進行聚合而成之多孔性聚合物、日本專利第4651392號公報中所記載之四級銨鹽、活性碳、黏土礦物等。作為護膚劑，可使用日本專利第4084278號公報中所記載之植物萃取物、膠原蛋白、天然保濕成分、保濕劑、角質軟化劑、消炎劑等。 上述血球凝集劑組合物中所占之陽離子性聚合物之比例較佳為1質量%以上，進而較佳為3質量%以上，進而更佳為5質量%以上。又，較佳為50質量%以下，進而較佳為30質量%以下，進而更佳為10質量%以下。藉由將上述血球凝集劑組合物中所占之陽離子性聚合物之比例設定為該範圍內，可對吸收性物品賦予有效量之陽離子性聚合物。 以上，對本發明進行了說明，但本發明不限於上述實施形態，可於不脫離本發明之主旨之範圍內適當地進行變更。例如，於肌膚側包芯片材之下方構件中之與吸收性芯體重疊之部分之全域或一部分配置血球凝集劑之態樣不限於第1實施形態或第2實施形態者，只要可形成與防漏槽8之整體或一部分重疊之凝集劑配置部，則可設為任意之態樣。例如，可以防漏槽8跨及全周而重疊之方式設置凝集劑配置部，亦可形成僅前方防漏槽82及後方防漏槽83之一者或兩者重疊之凝集劑配置部。又，可形成一對側方防漏槽81與前方防漏槽82及後方防漏槽83之一者或兩者重疊之凝集劑配置部，亦可形成取代側方防漏槽81之全長而僅側方防漏槽之中央圓弧狀部重疊之凝集劑配置部。 又，含有血球凝集劑之下方構件亦可為肌膚側包芯片材以外之構件、例如吸收性芯體或非肌膚側包芯片材，又，亦可使2個以上之下方構件含有血球凝集劑。例如，可為肌膚側包芯片材、吸收性芯體及非肌膚側包芯片材中之任意2個以上，亦可以跨及肌膚側包芯片材、吸收性芯體及非肌膚側包芯片材之全部之方式配置血球凝集劑。 又，血球凝集劑只要於下方構件中含有即可，不排除於正面片材中含有。 又，吸收性物品亦可為不具有側部防漏片材及利用其之防漏機制者，又，亦可為不具有側翼部者。又，本發明之吸收性物品除經期衛生棉以外，亦可為衛生護墊(陰道分泌物護墊)等。 關於上述之本發明之實施形態，本發明進而揭示以下之附記(吸收性物品等)。 ＜1＞ 一種吸收性物品，其係經血吸收用之吸收性物品，其包括：形成肌膚對向面之液體透過性之正面片材、形成非肌膚對向面之背面片材、及配置於該等兩片材間之吸收體，且具有沿穿著者之前後方向之縱向、及與該縱向正交之橫向，於上述肌膚對向面，上述正面片材陷入至上述吸收體而成之側方防漏槽於沿上述縱向之兩側分別連續地延伸，且配置於較上述正面片材靠近上述背面片材之位置之下方構件中包含血球凝集劑，上述下方構件中之配置有上述血球凝集劑之範圍與上述側方防漏槽具有重疊之部分。 ＜2＞ 如＜1＞所記載之吸收性物品，其中於與穿著者之排泄部對向之排泄部對向部，上述側方防漏槽具有朝上述橫向之外側凸狀地彎曲之中央圓弧狀部。 ＜3＞ 如＜2＞所記載之吸收性物品，其於上述中央圓弧狀部之前後分別具有具備朝橫向之外側凸狀地彎曲之俯視形狀的前方圓弧狀部及後方圓弧狀部，且該中央圓弧狀部與該前方圓弧狀部之連接部及上述中央圓弧狀部與上述後方圓弧狀部之連接部成為一對側方防漏槽之距離變窄之內縮部。 ＜4＞ 如＜3＞所記載之吸收性物品，其中上述吸收性物品具有較上述排泄部對向部靠穿著者之前側配置之前方部、及較該排泄部對向部靠穿著者之後側配置之後方部，且上述前方圓弧狀部與上述後方圓弧狀部分別位於上述前方部與上述後方部。 ＜5＞ 如＜2＞至＜4＞中之任一項所記載之吸收性物品，其中一對上述側方防漏槽之中央圓弧狀部之縱向之全長與凝集劑配置部重疊。 ＜6＞ 如＜1＞所記載之吸收性物品，其中於與穿著者之排泄部對向之排泄部對向部，上述側方防漏槽具有朝上述橫向之內側凸狀地彎曲之圓弧狀部。 ＜7＞ 如＜1＞至＜6＞中之任一項所記載之吸收性物品，其中上述下方構件係於吸收性物品之厚度方向上與上述正面片材鄰接之構件。 ＜8＞ 如＜1＞至＜7＞中之任一項所記載之吸收性物品，其中上述下方構件中之配置有上述血球凝集劑之範圍與上述側方防漏槽重疊之重複部分中之該血球凝集劑之每單位面積之存在量為6 g/m2
以上且80 g/m2
以下。 ＜9＞ 如＜1＞至＜8＞中之任一項所記載之吸收性物品，其中上述重複部分中之上述血球凝集劑之每單位面積之存在量多於不與上述側方防漏槽重疊之部分之該血球凝集劑之每單位面積之存在量。 ＜10＞ 如＜1＞至＜9＞中之任一項所記載之吸收性物品，其中上述血球凝集劑之重量平均分子量為2000以上且3000萬以下之陽離子性聚合物。 ＜11＞ 如＜10＞所記載之吸收性物品，其中上述血球凝集劑之重量平均分子量為1萬以上且2200萬以下、較佳為15萬以上且1000萬以下。 ＜12＞ 如＜2＞至＜11＞中之任一項所記載之吸收性物品，其中於上述排泄部對向部形成有與上述側方防漏槽於上述橫向上並列之第2防漏槽。 ＜13＞ 如＜12＞所記載之吸收性物品，其中於與穿著者之排泄部對向之排泄部對向部，上述側方防漏槽具有朝上述橫向之外側凸狀地彎曲之中央圓弧狀部，且以與該中央圓弧狀部於橫向上並列之方式形成有上述第2防漏槽。 ＜14＞ 如＜12＞或＜13＞所記載之吸收性物品，其中於上述側方防漏槽之橫向外側形成有上述第2防漏槽。 ＜15＞ 如＜13＞或＜14＞所記載之吸收性物品，其中上述中央圓弧狀部及第2防漏槽與跨及兩者間而連續之包含上述血球凝集劑之凝集劑配置部重疊。 ＜16＞ 如＜13＞或＜14＞所記載之吸收性物品，其中於上述中央圓弧狀部及第2防漏槽與於橫向上隔開間隙而形成之分開之包含上述血球凝集劑之凝集劑配置部重疊。 ＜17＞ 如＜1＞至＜16＞中之任一項所記載之吸收性物品，其包括將一對上述側方防漏槽之端部彼此於前方部側連結之前方防漏槽、及於後方部側連結之後方防漏槽而形成有環狀之防漏槽。 ＜18＞ 如＜1＞至＜17＞中之任一項所記載之吸收性物品，其中上述血球凝集劑之配置部係一對上述側方防漏槽之縱向之全長之50%以上且100%以下、較佳為70%以上且100%以下重疊。 ＜19＞ 如＜1＞至＜18＞中之任一項所記載之吸收性物品，其中上述吸收體係包含吸收性芯體、及覆蓋該吸收性芯體之包芯片材而成，且上述血球凝集劑包含於該包芯片材。 ＜20＞ 如＜19＞所記載之吸收性物品，其中上述吸收性芯體包含紙漿纖維與高吸收性聚合物之混合纖維堆積體。 ＜21＞ 如＜19＞或＜20＞所記載之吸收性物品，其中上述包芯片材之被覆上述吸收性芯體之肌膚對向面側的肌膚側部分之全域成為包含血球凝集劑之凝集劑配置部。 ＜22＞ 如＜1＞至＜21＞中之任一項所記載之吸收性物品，其中上述吸收性物品係經期衛生棉。 ＜23＞ 一種吸收性物品，其係經血吸收用之吸收性物品，其包括：形成肌膚對向面之液體透過性之正面片材、形成非肌膚對向面之背面片材、及配置於該等兩片材間之吸收體，且具有沿穿著者之前後方向之縱向、及與該縱向正交之橫向，於上述肌膚對向面，上述正面片材陷入至上述吸收體而成之側方防漏槽於沿上述縱向之兩側分別連續地延伸，且配置於較上述正面片材靠近上述背面片材之位置之下方構件中包含陽離子性聚合物，上述下方構件中之配置有上述陽離子性聚合物之範圍與上述側方防漏槽具有重疊之部分。 ＜24＞ 如＜23＞所記載之吸收性物品，其中上述陽離子性聚合物係四級銨鹽均聚物、四級銨鹽共聚物或四級銨鹽縮聚物。 ＜25＞ 如＜24＞所記載之吸收性物品，其中上述陽離子性聚合物之分子量為2000以上且3000萬以下。 [實施例] 以下，藉由實施例更加詳細地對本發明進行說明。然而，本發明之範圍不受該實施例任何限制。 [實施例1] 製作圖1所示之形態之經期衛生棉，將其設為實施例1之樣品。經期衛生棉之厚度係設為4.2 mm。作為吸收體4，使用製成包含木漿纖維及高吸收性聚合物之混合纖維堆積體(吸收性芯體)，並以基重為16 g/m2
且厚度為0.3 mm之薄紙(衛生紙)被覆該混合纖維堆積體而成者。混合纖維堆積體中，木漿纖維之基重為300 g/m2
，高吸收性聚合物之基重為56 g/m2
。作為高吸收性聚合物，使用日本觸媒股份有限公司製造之適於衛生用品之通用等級之高吸收聚合物。 使用將下述配方之血球凝集劑製備成水溶液，將5 g溶解於100 g之離子交換水中，使該溶液含浸於吸收體4中之包芯片材整個面後，於30℃10%RH之條件下靜置24小時而使其乾燥，乾燥後之包芯片材中所含有之每單位面積之血球凝集劑之存在量成為12 g/m2
者。 ・血球凝集劑之配方 Unisence FPA1002L(Senka股份有限公司；聚二烯丙基二甲基氯化銨(重量平均分子量：60萬、流動電位：7856 μeq/L)) [實施例2] 作為圖3所示之形態，關於乾燥後之包芯片材中所含有之每單位面積之血球凝集劑之存在量，使與防漏槽之沿縱向延伸之部分重疊之重複部分中之血球凝集劑之每單位面積之存在量成為50 g/m2
，且使包芯片材之除此以外之部分之每單位面積之血球凝集劑之存在量成為12 g/m2
，除此以外，以與實施例1相同之方式製作經期衛生棉，將其設為實施例2之樣品。 [實施例3及4] 於實施例1中，將血球凝集劑之配方替換為以下者，除此以外，以相同之方式製作各經期衛生棉。 ・實施例3：將Lubrizol Japan公司製造之商品名Merquat100進行乾燥而獲得之聚二烯丙基二甲基氯化銨(重量平均分子量15萬) ・實施例4：將Nittobo Medical公司製造之商品名PAS-H-5L進行乾燥而獲得之聚二烯丙基二甲基氯化銨(重量平均分子量：3萬、流動電位7447 μeq/L、IOB2.1) [實施例5] 形成如圖8所示之於隔著排泄位置部P之兩側沿縱向延伸之設為直線形狀之防漏槽，除此以外，以與實施例1相同之方式製作經期衛生棉，設為實施例5之樣品。 [比較例1] 不於包芯片材塗佈血球凝集劑，除此以外，以與實施例1相同之方式製作經期衛生棉，將其設為比較例1之樣品。 [評價試驗] 藉由下述方法對實施例及比較例之經期衛生棉評價防漏性。將其結果示於下述表1。再者，作為模擬血液，使用上述模擬血液(黏度8 mPa・s)。 ＜防漏性之評價方法＞ 將重複進行穿著動作直至表面材與吸收體之間產生間隙之各經期衛生棉以正面片材2側朝向上側之方式固定於相對於水平面具有45°之角度之斜面上。歷時10秒對該狀態之經期衛生棉之排泄位置部滴加3 g之模擬血液。放置3分鐘後，觀察各衛生棉之肌膚對向面，以目視觀察液體是否越過防漏壁而擴散。於液體未越過防漏槽而擴散之情形時，再次歷時10秒滴加3 g之模擬血液並放置3分鐘，重複進行該作業直至液體越過防漏槽而擴散，根據以下之基準進行評價。 A：12 g以上 B：6 g以上～未達12 g C：未達6 g 由表1所示之防漏性之評價可知：於實施例1～5之經期衛生棉中，與比較例1之經期衛生棉相比，由防漏槽產生之液體之擴散抑制效果提高。尤其，將防漏槽於排泄位置部P處設為外凸或內凸之曲線形狀者(實施例1～4)與將防漏槽設為直線形狀者(實施例5)相比顯示較高之防漏性。 上述試驗係假想因穿著時之動作等而產生之外力使防漏槽之表面材與吸收體之壓接部產生間隙，強制性地使各經期衛生棉之防漏槽中之表面材與吸收體之間剝離而進行評價。 [表1]
[實施例6] 製作圖8所示之形態之經期衛生棉，將其設為實施例6之樣品。具體而言，如圖8所示般將一對側方防漏槽81、81設為直線狀，除此以外，以與實施例1相同之方式製作於包芯片材之全域塗佈有血球凝集劑之經期衛生棉，將其設為實施例6之樣品。 [比較例2] 不於包芯片材塗佈血球凝集劑，除此以外，以與實施例6相同之方式製作經期衛生棉，將其設為比較例2之樣品。 ＜靜態最大吸收量＞ 將經期衛生棉之樣品固定於丙烯酸板，從排泄位置部注入3 g之模擬血液，液體注入結束後靜置3分鐘，其後，以每單位平方厘米成為50 g之方式對液排泄位置施加1分鐘負荷。之後重複進行該操作，於從經期衛生棉之側翼部滲出有液體之時間點結束，設為靜態最大吸收量。 ＜動態擴散長度＞ 將經期衛生棉之樣品固定於經期短褲，穿著於人體之動態模型。使動態模型開始步行動作，於步行動作開始1分鐘後，從液體排泄位置部注入3 g之模擬血液，使其自步行動作開始後合計步行3分鐘(第1次)。之後，重複進行2次該操作後，自動態模型取下衛生棉，測定衛生棉之因模擬血液而著色之部分之衛生棉橫向及衛生棉縱向之長度，將其設為橫向及縱向之動態擴散長度。 [表2]
由表2所示之靜態最大吸收量之評價可知：於實施例6之經期衛生棉中，與比較例2之經期衛生棉相比，靜態最大吸收量提高。又，可知由防漏槽產生之液體之擴散抑制效果提高。進而，由動態擴散長度之評價可知：實施例6與比較例2相比向橫向之擴散得到控制，於縱向上擴散。由上述評價之結果可知：由防漏槽產生之液體之擴散抑制效果提高，並且吸收性能提高。 [產業上之可利用性] 根據本發明之吸收性物品，經血自防漏槽之內側向外側之移動得到抑制，可維持良好之防漏性能。In Patent Documents 2 and 5, there is no description of a structure that increases the rate of absorption of blood or the amount of absorption except that a water-soluble metal compound is used as a coagulant. On the other hand, in the absorbent article described in Patent Document 3, not only the shape of the embossing is unknown, but also the blood gelling agent is concentrated at or along the end of the embossed thread, so it is formed in that part Agglomerates do not make full use of the absorber. Furthermore, in Patent Document 4, although the red blood cell mass is captured between the fibers of the non-woven mesh, it is difficult to continuously ensure the absorption of blood by this mechanism. Furthermore, regarding the absorbent articles described in Patent Documents 3 and 4, although it is described that a fluid treatment agent containing polycations can be used, in fact, only information when a non-ionic treatment material is disclosed. In addition, these techniques are also disadvantageous in that the absorption of blood into the absorber is impeded due to the decrease in the liquid permeability of the blood agglutinate of the part facing the excretion position of the absorbent article, and the absorption of blood to the absorber is hindered. Absorption takes time, or the amount of blood absorbed decreases. In addition, in Patent Documents 1 to 5, there is no description of measures to reduce the leakproofness by using a blood modifying agent for the peeling between the front sheet and the absorber generated in the leakproof tank. Therefore, the subject of the present invention is to provide an absorbent article that more effectively exhibits the effect of improving the absorption performance by using a hemagglutinating agent. The subject of the present invention is to provide an absorbent article capable of solving the solving problems of the prior art. Hereinafter, the absorbent article for absorbing menstrual blood according to the present invention will be described with reference to the drawings based on its preferred embodiment. The absorbent article for menstrual blood absorption is contained in a menstrual article. As shown in Figs. 1 and 2, the menstrual tampon 1 (hereinafter also referred to as "tampon 1") as the first embodiment of the present invention is provided with a front sheet 2 which has liquid permeability to form a skin-facing surface. A non-skin-facing back sheet 3 and a liquid-retaining absorbent 4 disposed between the two sheets 2 and 3 are formed. The front sheet 2, the absorber 4, and the back sheet 3 are integrated to constitute an absorbent body 5. A side leakage preventing sheet 6 is arranged on the front sheet 2 side of both sides in the longitudinal direction of the absorbent body 5. The side leak-proof sheet 6 has a free end 61 that is not joined to the front sheet 2 and a fixed end 62 that is joined to the front sheet 2. When in use, the fixed end 62 and the free end 61 are separated from the front sheet 2. To form a leakproof bag (not shown) to prevent leakage to the side. A non-skin contact surface of the absorbent body 5 is provided with a body adhesive portion (not shown) for fixing the crotch portion of the shorts. The sanitary napkin 1 has a pair of side flap portions 7 on both side portions in the longitudinal direction X. On the surface on the back sheet 3 side of the pair of side wing portions 7, a side wing portion adhesive portion (not shown) for fixing to the non-skin facing surface of the crotch portion of the shorts is provided. As the front sheet 2, the back sheet 3, and the side leak-proof sheet 6, various sheets and the like previously used for absorbent articles such as menstrual tampons can be used without particular limitation. For example, as the front sheet 2, a single-layer or multi-layer nonwoven fabric or an apertured film can be used. The front sheet 2 may be one having unevenness on the skin abutting surface side, or one having an oil agent adhered to the surface of the constituent fibers. In the case where the front sheet 2 has a multilayer structure, as the front sheet 2, an uneven sheet having the first fiber layer located on the side close to the wearer's skin, and the first fiber layer located on the side of the wearer can be used. The second fiber layer on the far side of the skin. The two fiber layers are integrated in the thickness direction by a plurality of joints formed locally. The first fiber layer is partially convex between the multiple joints. The ground is raised to form the convex portion having the uneven shape. As the uneven sheet having a convex portion having a solid structure, for example, those described in Japanese Patent Laid-Open No. 2007-182662 or Japanese Patent Laid-Open No. 2002-187228 can be used. As the back sheet 3, a resin film, a resin film, a nonwoven fabric, a laminated body, or the like can be used. The back sheet 3 is made of liquid impermeability (including liquid impermeability) or water repellency, and it is also preferable to use a moisture-permeable resin film or the like. As the side leakage preventing sheet 6, a laminated nonwoven fabric having a high water pressure resistance, a laminated body of a resin film and a nonwoven fabric, and the like can be used. As shown in FIG. 1, the sanitary napkin 1 has a longitudinal direction X corresponding to the front-back direction of the wearer, and a transverse direction Y orthogonal to the longitudinal direction X. The sanitary napkin 1 has, in the longitudinal direction X, a drainage portion facing portion B having a drainage position portion P in which a liquid drainage portion of a wearer, such as a central portion in the width direction (lateral direction) and a vaginal opening, faces each other. The front facing portion B is disposed on the front side (front side) of the wearer, and the front facing portion B is disposed on the back side (rear side) of the wearer than the excretory facing portion B. That is, the sanitary napkin 1 is sequentially divided into a front portion A, an excretory portion facing portion B, and a rear portion C in the longitudinal direction X. In the absorbent article of the present invention, the skin-facing surface is the surface of the sanitary napkin 1 or its constituent members (for example, the front sheet 2 and the absorbent core 41) that faces the skin side of the wearer when the sanitary napkin 1 is worn. The non-skin-facing surface is the side of the sanitary napkin 1 or its constituent members that faces the side opposite to the skin side (usually the side of the clothes being worn) when wearing the sanitary napkin 1. The excretion position portion P refers to a portion where the menstrual blood is directly provided when the absorbent article such as sanitary napkin 1 is worn and placed against the wearer's liquid excretion portion, and is usually located in the longitudinal X and width of the excretion portion facing portion B Center of direction Y. In the sanitary napkin 1 of this embodiment, the excretion position portion P has an elliptical shape, and has a long axis 3 cm along a central line extending in the width direction of the sanitary napkin 1 in the longitudinal direction X, and along the lateral direction. The minor axis of Y is 2 cm. Further, in the sanitary napkin 1, the center point of the excretion position portion P in the longitudinal direction X is preferably located approximately on the longitudinal bisector of the side flap portion. Here, the so-called "approximately located" means that it can also be shifted forward and backward by 15 mm from the bisector, but in this case, the excretion position portion P also falls within the excretion portion facing portion B and exists. . In the absorbent article of the present invention, when the so-called excretory portion facing portion B has a so-called side flap like the sanitary napkin 1 of the present embodiment, it means that the side with the side flap in the longitudinal direction X of the absorbent article. Region (a region sandwiched between the root portion in the longitudinal direction X of one wing portion and the root portion in the longitudinal direction X of the other wing portion). In addition, when the absorbent article does not have a side flap, it means that when the absorbent article is folded into a three-fold single packaging form, two folding curves (not shown) that cross the absorbent article in the transverse direction Y are generated, and The area surrounded by the first fold curve and the second fold curve from the front end in the longitudinal direction X of the absorbent article. In the sanitary napkin 1, the front sheet 2 covers the entire area of the skin-facing surface of the absorbent body 4, and the back sheet 3 covers the entire area of the non-skin-facing surface of the absorbent body 4. The portions of the front sheet 2 and the back sheet 3 extending from both ends of the longitudinal direction X of the absorbent body 4 are joined to each other. In addition, the back sheet 3 and the side leak-proof sheet 6 are joined to each other at portions extending from both edges of the absorbent body 4 in the longitudinal direction X to the outer side in the lateral direction Y. In this manner, the absorbent body 4 is sandwiched between the front sheet 2 and the back sheet 3. The joining between the sheets constituting the sanitary napkin 1 is performed by an arbitrary joining method such as an adhesive, heat sealing, or ultrasonic sealing. In the menstrual period absorbent article of the present invention, in the excretory portion facing portion B, the lateral leak-proof grooves 81 formed by the front sheet 2 sinking into the absorbent body 4 are continuously formed on both sides in the longitudinal direction X. . As shown in FIG. 1, the sanitary napkin 1 of the first embodiment has a side leak-proof side surface formed by the front sheet 2 sinking into the absorbent body 4 around the above-mentioned excretion position portion P of the sanitary napkin 1. Slot 81. More specifically, an annular leak-proof groove 8 is formed on the skin-opposing surface of the sanitary napkin 1. The annular leak-proof groove 8 is provided with a pair of lateral leak-proof grooves 81, 81, extending in the longitudinal direction X. A pair of side leak-proof grooves 81 and 81 are connected to each other at the front portion A side with a front leak-proof groove 82 and a pair of side leak-proof grooves 81 and 81 are connected to each other at a rear portion C side Following side leak-proof groove 83. Each of the pair of lateral leak-proof grooves 81 extends along the longitudinal direction X of the sanitary napkin 1 on both sides in the lateral direction Y across the excretion position portion P, respectively. The pair of side leak-proof grooves 81 and 81 preferably extend in the longitudinal direction X at least on both sides of the excretory portion facing portion B through the excretion position portion P, respectively. The side leak-proof groove 81 preferably extends from the draining portion facing portion B and the front portion A or the rear portion B, and more preferably spans the front portion A, the draining portion facing portion B, and The rear portion C extends. The pair of side leak-proof grooves 81 and 81 are preferably connected to each other by the front-side front leak-proof groove 82 and the front-side A-side end via the more-drained-position portion P, and the more-drained-position portion P passes through the rear side leakage prevention groove 83 and the end portions on the rear side C side are connected to each other. Each of the pair of lateral leak-proof grooves 81 has a plan view that is convexly curved toward the outer side of the lateral Y at the part facing the excretory part B, preferably the part on both sides of the lateral Y through the excretion position part P. The central arc-shaped portion 81b of the shape has a front arc-shaped portion 81a and a rear arc-shaped portion having a plan shape that is convexly curved toward the outside of the lateral Y, respectively, before and after the central arc-shaped portion 81b in the longitudinal direction X. Department 81c. Each of the pair of side leak-proof grooves 81 has a plan view shape in which the three arc-shaped portions (outwardly curved portions) 81a, 81b, and 81c that are convexly curved toward the outside of the lateral Y are connected to each other in the vertical X. The connection portion between the central arc-shaped portion 81b and the front arc-shaped portion 81a, and the connection portion between the central arc-shaped portion 81b and the rear arc-shaped portion 81c become a narrowed portion where the distance between the pair of lateral leak-proof grooves 81 is narrowed. . Regarding the leakage prevention groove 8, in any one of the side leakage prevention groove 81, the front leakage prevention groove 82, and the rear leakage prevention groove 83, the skin facing side of the absorbent body 4 is recessed together with the front sheet 2. Groove-shaped, the portions of the absorbent body 4 in which the leak-proof grooves 81, 82, and 83 are formed, respectively, are denser than the portions of the absorbent body 4 located on both sides of the leak-proof grooves 81, 82, and 83, respectively. Into. The leak-proof groove 8 can be formed, for example, by applying pressure to a laminate of the front sheet 2 and the absorbent body 4 or embossing with heating and pressure. The main function of the leak-proof groove 8 is to suppress the diffusion of the liquid in the planar direction of the sanitary napkin 1. As shown in FIG. 2, the absorbent body 4 of the sanitary napkin 1 includes an absorbent core 41 containing pulp fibers, and a core material 42 covering the absorbent core 41. The chip material 42 in this embodiment has a skin-side portion 42a covering the skin-facing side of the absorptive core 41, and a non-skin-facing surface side wound around the absorptive core 41 to cover the The non-skin-facing non-skin-side portion 42b of the absorptive core 41. In addition, the cover material 42 has an overlapping portion 42c between the sheets in the non-skin-side portion 42b. The encapsulating core material covering the absorptive core body 41 may cover the entire absorptive core body 41 with a single sheet, or may cover the entire absorptive core body 41 with two or more sheets. For example, the skin-facing surface side and the non-skin-facing surface side of the absorbent core 41 may be covered with different sheets. Regardless of the number of covered sheets for the absorptive core 41, the encapsulating sheet that covers the skin-facing side of the absorptive core 41 is also referred to as the skin-side enclosing sheet 42a, and will cover the absorptive core. The non-skin-facing portion of 41 is also referred to as the non-skin-side encapsulating material 42b. In the sanitary napkin 1 of the first embodiment, as shown in FIG. 2, the entire area of the skin-side portion (skin-side encapsulating material) 42 a of the skin-facing surface of the absorbent core 41 in the encapsulating material 42 becomes An agglutinating agent disposing section 9 containing a blood agglutinating agent. The skin-side wrapping sheet material 42 a is one of the lower members arranged in the thickness direction of the sanitary napkin 1 nearer to the back sheet 3 than the front sheet 2. The sanitary napkin 1 includes a skin-side covering material 42a, an absorbent core 41, and a non-skin-side covering material 42b as lower members. It is preferable that the agglutinating agent disposing portion 9 including the hemagglutinating agent is formed at least on the skin-side encapsulating material 42a which is a lower member adjacent to the front sheet 2 in the thickness direction of the absorbent article. The agglutinating agent disposing portion 9 including the hemagglutinating agent may be formed only on the skin-side encapsulating core material 42a, or may be formed on the skin-side encapsulating core material 42a and the absorptive core 41, or may be across the skin-side encapsulating core material 42a and absorb. The core body 41 and the non-skin-side core material 42b are formed. In the sanitary napkin 1 of the first embodiment, the agglutinating agent disposition portion 9 of the skin-side encapsulating material 42a is a range in which the hemagglutinating agent is disposed in the lower member. When the sanitary napkin 1 is viewed from the top, the agglutinating agent disposition portion 9 and The domains in the slot 8 overlap. However, the first embodiment is not limited to this, and the agglutinating agent disposition portion 9 may include a portion existing on the lateral center side of the excretory portion facing portion B without overlapping with the side leak-proof grooves 81, 81, and the like. It is configured by being spaced apart from the side leak-proof grooves 81 and 81. In the sanitary napkin 1A of the second embodiment, as shown in FIG. 3 and FIG. 4, a pair of spaced-apart band-shaped portions in the skin-side encapsulating material 42 a become the agglutinating agent disposing portions 9A, 9A containing the hemagglutinating agent. . The agglutinating agent disposition portions 9A and 9A are formed by extending in the longitudinal direction X on both sides of each side of the excretion position portion P when the sanitary napkin 1 is viewed in plan. In the sanitary napkin 1A of the second embodiment, the agglutinating agent is arranged in the agglutinating agent disposing portions 9A and 9A of the skin-side encapsulating material 42a, as shown in FIG. 3, when the sanitary napkin 1 is viewed from the top. The agglutinating agent disposition portions 9A and 9A overlap with one of the side leak-proof grooves 81 and 81 extending in the longitudinal direction X in the leak-proof groove 8. The sanitary napkin 1A according to the second embodiment is the same as the sanitary napkin 1 according to the first embodiment, and the description of the first embodiment can be appropriately applied. The entire area of the side leak-proof groove 81 in the sanitary napkin 1 of the first embodiment overlaps with the agglutinating agent disposing unit 9 as a range where the hemagglutinating agent is disposed. However, in the sanitary napkin 1A of the second embodiment, A region where the blood agglutinating agent is not arranged is formed in the central part of the transverse direction Y of 1A, and the leakage preventing groove 8 may have portions that do not overlap the aggregating agent disposing portions 9A and 9A in the front leakage preventing groove 82 and the rear leakage preventing groove 83. Furthermore, in any of the sanitary napkin 1 of the first embodiment and the sanitary napkin 1A of the second embodiment, the menstrual blood is prevented from moving from the inside of the leak prevention groove to the outside in the transverse direction Y, and good leakage prevention performance is maintained. From the viewpoint, it is preferable that the entire length of the longitudinal X of the central arc-shaped portion 81b of the pair of side leak-proof grooves 81, 81 overlaps with the agglutinating agent disposition portion 9 or 9A, and it is preferable that the pair 50% or more and 100% or less of the total length of the longitudinal X of the drain grooves 81 and 81 overlaps with the agglutinating agent disposition portion 9 or 9A, and more preferably 70% or more and 100% or less overlaps with the agglutinating agent disposition portion 9 or 9A. The core material is used for the purpose of improving the shape retention of the absorptive core with insufficient shape retention or preventing leakage of the constituent materials of the absorptive core when used alone, and uses fiber sheets such as thin paper or non-woven fabric. Examples of cellulose fibers constituting tissue paper include wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate fibers. Examples of raw material pulp for cellulose fibers include wood pulp such as coniferous kraft pulp or broadleaf kraft pulp, non-wood pulp such as cotton pulp, and grass pulp. These cellulose fibers can be used alone or in combination of two or more. From the viewpoint of improving the strength, a small amount of non-cellulose-based fibers may be blended. Examples of the non-cellulose-based fibers include polyolefin-based fibers such as polyethylene and polypropylene, and condensation-based fibers such as polyester and polyamide. Among the constituent fibers of the tissue paper, the proportion of the cellulose-based fibers is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and still more preferably 100% by mass. Non-woven fabrics can also be used as the core material. As the type of the non-woven fabric, a non-woven fabric made by various manufacturing methods can be used without particular limitation, and examples thereof include a spunbond non-woven fabric, a melt-blown non-woven fabric, and a non-woven fabric obtained by intersecting constituent fibers of a fiber web by high-speed water treatment. That is, a spunlace nonwoven fabric, a nonwoven fabric obtained by thermally fusing constituent fibers of a fiber web by hot air treatment, that is, a hot-air nonwoven fabric, a nonwoven fabric obtained by adhering constituent fibers of a fiber web with an adhesive, that is, a resin-bonded nonwoven fabric, and the like. A spunlace nonwoven fabric, a hot air nonwoven fabric, and a resin-bonded nonwoven fabric can be produced by a carding machine or an air spinning method in which fibers are stacked in the air. Non-woven raw material fibers include cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate, or polyolefins such as polyethylene and polypropylene, and polyethylene terephthalate. Synthetic fiber of synthetic resins such as polyester and nylon. As the synthetic fiber, a core-sheath type or a side-by-side type composite fiber may be used. Among these, for the same reason as the use of tissue paper, in the case of non-woven fabrics of various manufacturing methods, it is also preferable that the raw material fiber is a cellulose-based fiber. Among the constituent fibers of the nonwoven fabric, the proportion of the cellulose-based fibers is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and still more preferably 100% by mass. Non-woven raw material fibers can be used alone or in combination of two or more. The absorbent core 41 of the sanitary napkin 1 of this embodiment includes a mixed fiber stack of pulp fibers and a superabsorbent polymer. The mixed fiber stacking system is manufactured by a known drum-type fiber stacking device provided with a fiber stacking drum having a stacking recess on the peripheral surface. The fiber stacking system sucks from the bottom surface of the stacking recess and uses it as a material for forming an absorbent core. The pulp fibers and the superabsorbent polymer are supplied to the peripheral surface of the fiber stacking drum in a scattered state, and the forming material of the absorbent core is accumulated in the recessed portion for agglomeration, and then obtained by demolding from the recessed portion for agglomeration. The absorbent core 41 of the sanitary napkin 1 of this embodiment may also be a separate fiber stack of pulp fibers that do not contain a superabsorbent polymer. Examples of the pulp fibers constituting the absorbent core 41 include cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate. These fibers may be used alone or in combination of two or more. As raw material pulp of the pulp fiber, non-wood pulp such as wood pulp such as coniferous kraft pulp or broadleaf kraft pulp, cotton pulp, or grass pulp can be listed. From the viewpoint of improving the strength, in addition to pulp fibers containing cellulose-based hydrophilic fibers, a small amount of polyolefin-based fibers such as polyethylene and polypropylene, polyester, and polyfluorene may be mixed in the absorbent core 41. Synthetic fibers such as condensation fibers such as amines. Furthermore, the proportion of pulp fibers (cellulose-based fibers), especially wood pulp fibers, of the absorbent core in the present invention is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass. Mass% or less, more preferably 100% by mass. The absorbent core 41 may contain a superabsorbent polymer (water-absorbing polymer). As the superabsorbent polymer, particles are generally used, but fibers may also be used. When a particulate superabsorbent polymer is used, its shape may be any of a spherical shape, a block shape, a bag shape, and an irregular shape. As the superabsorbent polymer, a polymer or copolymer of acrylic acid or an alkali metal salt of acrylic acid can be generally used. Examples thereof include polyacrylic acid and a salt thereof, and polymethacrylic acid and a salt thereof. As the polyacrylate or polymethacrylate, a sodium salt can be preferably used. In addition, acrylic acid or methacrylic acid may be used in combination with maleic acid, itaconic acid, acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, and 2- (meth) acrylic acid ethylsulfonic acid. A copolymer obtained by copolymerizing a comonomer such as 2-hydroxyethyl (meth) acrylate or styrene sulfonic acid within a range that does not reduce the performance of the superabsorbent polymer. By containing a water-absorptive polymer, a large amount of blood, such as blood, can be absorbed more quickly and held. If necessary, a deodorant, an antibacterial agent, or the like may be blended in the absorbent core 41. The method for forming the agglutinating agent disposing portion by including a hemagglutinating agent as a constituent member of sanitary napkins such as the core material 42 is not particularly limited. For example, a hemagglutinating agent containing a cationic polymer is dissolved in water, ethanol, and the like. The solution is prepared in a suitable solvent such as a mixed solution, and the solution is adhered to a desired portion of the component, and then the solvent is removed by drying to uniformly dispose the hemagglutinating agent in the agglutinating agent disposing section. In terms of better. As a method of adhering a solution to a constituent member, various methods of applying a solution to a specific part of a constituent member can be used. For example, a spray method, a dipping method, a transfer method, a nozzle coating, a gravure coating, an inkjet method, a screen printing, etc. are used to apply a liquid to a specific portion of a constituent member using a known liquid coating device. The drying may be any one of drying by heating, drying under reduced pressure, and drying by combining heating and reduced pressure, but it may be natural drying instead of forced drying. The sanitary napkins 1 and 1A of the first and second embodiments are used by being fixed to the crotch portion and the like of shorts in the same manner as a normal menstrual sanitary napkin. According to the sanitary napkin 1 of the first embodiment and the sanitary napkin 1A of the second embodiment, even when the front sheet 2 and the absorbent body 4 are peeled off in the leak-proof groove 8 due to external force applied during wearing, the same applies. As shown in FIG. 5, the blood cell agglutinating agent contained in the lower member such as the skin-side encapsulating material 42 a acts on the menstrual blood 11 entering the gap between the front sheet 2 and the absorber 4, and the absorber in or near the gap An agglutination mass 16 of red blood cells is generated in 4, thereby preventing menstrual blood 11 from spreading beyond the leak prevention groove 8. This prevents leakage such as side leakage. When a gap in the thickness direction of the absorbent body 4 occurs in the leak-proof groove 8 formed by compressing and compressing the front sheet 2 and the absorbent body 4 integrally, similarly, the skin-side core material 42a, etc. The hemagglutinating agent contained in the lower member acts on the menstrual blood 11 entering the gap of the absorbent body 4, and a red blood cell agglutination mass 16 is generated in the absorbent body 4 in or near the gap, thereby preventing the menstrual blood 11 from passing through the leak prevention groove. 8 while spreading. This prevents leakage such as side leakage. From the viewpoint of effectively suppressing the diffusion of menstrual blood through the gap between the front sheet 2 and the absorbent body 4 generated in the leak-proof groove 8 by generating agglomerates 16 of red blood cells, the aggregation of the underlying components such as the skin-side encapsulating material 42a The agent disposing portion 9 or 9A preferably satisfies any one or more of the following conditions (1) to (3). (1) The amount of blood agglutinating agent per unit area in the repeating portion of the agglutinating agent disposition portion 9 or 9A overlapping the portion of the leak-proof groove 8 extending in the longitudinal direction X (lateral leak-proof groove 81) is 6 g / m 2 Above 80 g / m 2 Below, more preferably 12 g / m 2 Above 70 g / m 2 the following. The amount of the hemagglutination agent mentioned here refers to the pure amount of the cationic polymer when the hemagglutination agent is a cationic polymer. The amount per unit area of the hemagglutination agent is measured as follows . [Measurement method] After disposing the solution prepared by dissolving the cationic polymer, it was left to stand for 24 hours at 30 ° C and 10% RH to dry it. The agglutinating agent placement portion was cut out, and its area was measured to compare the agglutination The weight of the agent before and after the preparation, so as to calculate the amount of the hemagglutinating agent per unit area contained after drying. (2) The amount of hemagglutinating agent per unit area in the overlapping portion of the agglutinating agent disposition portion 9 or 9A overlapping with the portion extending in the longitudinal direction X of the leakage preventing groove 8 (lateral leakage preventing groove 81) is more than that of agglutination. The amount of the blood cell agglutinating agent per unit area in the agent disposing portion 9 or 9A that does not overlap with the leak prevention groove 8. By having the repeating portion concentratedly contain more hemagglutinating agents, the total amount of hemagglutinating agents used can be suppressed, and the ability to produce agglomerates 16 of red blood cells can be effectively improved and the leak-proof effect can be utilized. (3) The molecular weight of the cationic polymer used as the hemagglutinating agent is preferably 2,000 or more, more preferably 10,000 or more, and still more preferably 150,000 or more. The upper limit of the molecular weight is preferably 30 million or less, more preferably 22 million or less, and even more preferably 10 million or less. Moreover, it is preferably 2,000 or more and 30 million or less, further preferably 10,000 or more and 22 million or less, and still more preferably 150,000 or more and 10 million or less. The sanitary napkin 1 and the front sheet 2 of 1A are preferably hydrophilic as a whole, and preferably overlap with at least the agglutinating agent disposition portions 9, 9A and the leak-proof groove 8, especially the side leak-proof groove 81. The part is hydrophilic. If the front sheet 2 is hydrophilic, when the hydrophilic menstrual blood diffuses in the absorbent body, it can also diffuse efficiently in the side leak-proof grooves 81 that partially overlap or partially overlap with the agglutinating agent placement portion 9A. As a method for making the whole or a part of the front sheet 2 hydrophilic, a method including using a non-woven fabric mainly composed of cellulose-based fibers such as wood pulp fibers, reed fibers, cotton fibers, and cellulose acetate fibers, Or use a hydrophilic oil to hydrophilize polyolefin fibers such as polyethylene and polypropylene, synthetic fibers such as polyester and polyamide, and other synthetic fibers such as non-woven fabrics that are mainly composed of fibers as the front sheet 2 . In the sanitary napkin 1 of the first embodiment and the sanitary napkin 1A of the second embodiment, as described above, one of the leak-proof grooves 8 and more specifically, the leak-proof grooves 8 is opposite to the lateral leak-proof grooves 81. The excretion position portion P has a central arcuate portion 81b having a plan shape curved convexly toward the outside of the lateral Y, and portions located on both sides of the lateral Y. In the absorbent article of the present invention, the leak-proof groove 8 or a pair of lateral leak-proof grooves 81 has arc-shaped portions 81b that are convexly curved outwardly on both sides of the drain position portion P. The external force applied to the center of the lateral portion of the sanitary napkin during wearing from the horizontal Y to the right will cause the sanitary napkin to swell toward the wearer's skin side, so the external force is dispersed, and the external force applied to the side leak-proof groove 81 is reduced. As a result, the degree and frequency of occurrence of gaps in the front sheet in the lateral leak-proof grooves 81 from the absorbent body or the gaps generated in the pressure-compressed part of the absorbent body are reduced. Therefore, it has the advantages of preventing the movement of the liquid by using the leak-proof groove, and further improving the leak-proof performance of the absorbent article, and is therefore preferable. In addition, when the hemagglutination agent is also disposed on the inner side of the lateral leak prevention groove 81 as in the first embodiment and the second embodiment, menstrual blood is likely to agglutinate with the blood cells before reaching the lateral leak prevention groove 81. The agent is contacted to separate the agglutinate and plasma components. Therefore, the side leakage preventive grooves 81 and 81 have a shape that is convexly curved toward the outside of the lateral Y, and the side leakage preventive grooves 81 and 81 having the shape sandwich the excretion position portion P to make the plasma component. It is easy to spread in the longitudinal direction X along the side leakage preventing grooves 81 and 81, and it is difficult to generate side leakage. In addition, the agglomerates in the excretion site portion P and its surrounding area generated at the beginning of wearing will inhibit the menstrual blood that continues to be excreted from spreading to the outside of the lateral Y, and can function as a double leak-proof mechanism with the side leak-proof groove 81. It is effective to suppress side leakage of menstrual blood when wearing for time. Next, menstrual tampons as the third and fourth embodiments of the absorbent article of the present invention will be described. In the menstrual tampons of the third and fourth embodiments, a pair of lateral leak-proof grooves 81 is the same as the agglutinating agent disposition portion 9 of the sanitary napkin 1 of the first embodiment, that is, the chip material 42a is covered across the skin side. The agglutinating agent disposition portion formed by overlapping the entire part of the absorptive core body is overlapped, or the agglutinating agent disposition portions 9A and 9A are the same as those of the sanitary napkin 1A of the second embodiment, that is, locally formed on the skin side. The agglutinating agent disposition portions 9A and 9A of the portion of the core material 42a overlapping with the absorbent core overlap. Regarding the menstrual tampons of the third and fourth embodiments, the points different from the tampons 1 of the first or second embodiment will be described. For the same points, the same reference numerals will be given and the description will be omitted. Regarding aspects not specifically described, the description of the sanitary napkin according to the first or second embodiment may be appropriately applied. Fig. 6 is a plan view showing a menstrual tampon according to a third embodiment of the present invention. In the menstrual tampon 1B of the third embodiment (hereinafter, also referred to as sanitary tampon 1B), in the excretory portion facing portion B, the side leak-proof groove 81 has an arc that is convexly curved toward the inside of the lateral Y. Shaped portion (inwardly curved portion). Specifically, as shown in FIG. 6, one of the sanitary napkins 1B is opposite to the excretory portion facing portion B of the lateral leak-proof groove 81, preferably the portion on both sides of the lateral Y through the excretion position portion P becomes The arc-shaped portion (inwardly convex curved portion) 81d having a plan shape curved concavely toward the outside of the lateral Y is provided. In the absorbent article of the present invention, the leak-proof groove 8 or a pair of side leak-proof grooves 81 has an arc-shaped portion 81d that is concavely curved toward the outside on both sides of the drain position portion P. When wearing an external force to the center of the flanks of the sanitary napkin from the left and right in the horizontal direction during wearing, the external force will be dispersed in the front direction and the rear direction of the X direction of the sanitary napkin, so the external force applied to the side leak-proof groove 81 is reduced. As a result, the degree and frequency of occurrence of gaps in the front sheet in the lateral leak-proof grooves 81 from the absorbent body or the gaps generated in the pressure-compressed part of the absorbent body are reduced. Therefore, when the leak-proof groove has the above-mentioned convexly curved portion in this way, it has the advantages of preventing the movement of the liquid by the leak-proof groove, and further improving the leak-proof performance of the absorbent article. In addition, since the side leak-proof grooves 81 and 81 are convexly curved toward the excretion position portion P, when a large amount of menstrual blood is discharged in a short period of time, the menstrual blood easily diffuses along the leak-proof groove in the longitudinal direction X, and the menstrual blood is easy to contact the blood cells. The agglutinating agent comes into contact with each other to form an agglomerate in a region near the side leak-proof groove 81 and separates it into a plasma component. In particular, the plasma component easily diffuses in the longitudinal direction X. Moreover, in the excretory portion facing portion B, the absorbable area is wider on the outer side in the lateral Y than the lateral leak-proof groove 81. Therefore, even when a large amount of menstrual blood is discharged in a short period of time, it is difficult to generate a menstrual blood leak from the horizontal direction. Fig. 7 is a plan view showing a menstrual tampon according to a fourth embodiment of the present invention. The sanitary napkin 1C (hereinafter, also referred to as sanitary napkin 1C) of the fourth embodiment is the same as sanitary napkins 1 and 1A. The lateral leak-proof grooves 81 in the lateral direction Y are disposed on both sides of the drainage portion P, respectively. An arcuate portion 81b having a convex plan view shape is provided on the outside, and a second leak-proof groove 85 is provided on the outer side of each of the arcuate portions 81b and 81b in the lateral direction Y. The second leak-proof groove 85 has a plan view shape that is convexly curved toward the outside of the lateral Y in the same manner as the central arc-shaped portion 81b of the lateral leak-proof groove 81. The central arc-shaped portion 81b and the second leak-proof groove 85 It is formed by being aligned in the lateral direction Y, and is formed substantially parallel to each other. The central arc-shaped portion 81b and the second leak-proof groove 85 on the outer side thereof may overlap with the agglutinating agent disposition portion 9 or 9A continuous across the two, or may be separated from each other by forming a gap in the transverse direction Y. The agglutinating agent placement portions overlap. If there are double leak-proof grooves that overlap the agglutinating agent placement portion on both sides across the excretion position portion P, then when an external force is applied to the center of the side of the flanks of the sanitary napkin from the left and right in the transverse direction Y, the double leak-proof grooves The sanitary napkin is further promoted to swell toward the wearer's skin side, so the external force is dispersed, and the external force applied to the side leak-proof groove 81 is reduced. As a result, the degree and frequency of occurrence of gaps in the front sheet in the lateral leak-proof grooves 81 from the absorbent body or the gaps generated in the pressure-compressed part of the absorbent body are reduced. Therefore, it has the advantages of preventing the movement of the liquid by using the leak-proof groove, and further improving the leak-proof performance of the absorbent article, and is therefore preferable. Fig. 8 is a plan view showing a menstrual tampon according to a fifth embodiment of the present invention. The sanitary napkin 1D (hereinafter, sanitary napkin 1D) of the fifth embodiment is the same as the sanitary napkin 1 and 1A, and one of the leakage prevention grooves 8 is located in the lateral Y across the excretion position portion P across the leakage prevention groove 8. A pair of lateral leak-proof grooves 81 are formed on both sides of the two sides, respectively, and extend linearly in the longitudinal direction X. The pair of side leak-proof grooves 81 is the same as the agglutinating agent disposition portion 9 of the sanitary napkin 1 of the first embodiment, that is, across the entire area of the overlapping portion of the absorbent core of the core material 42a on the skin side. The formed agglutinating agent disposition portion overlaps, or the agglutinating agent disposition portion 9A, 9A is the same as the sanitary napkin 1A of the second embodiment, that is, a portion of the skin-side encapsulating material 42a overlapping with the absorbent core. The agglutinating agent disposition portions 9A and 9A overlap. In the sanitary napkin 1D shown in FIG. 8, a region in the leakage preventing groove 8 overlapping with the agglutinating agent disposition portion is indicated by reference numeral 89. When the blood agglutination agent is also arranged on the lateral inner side than the side leak prevention groove 81, before the menstrual blood reaches the side leak prevention groove, the menstrual blood is easily contacted with the blood agglutination agent and separated into agglomerates and plasma components to reach the side The plasma component of the square leak-proof groove spreads rapidly along the linear side leak-proof groove 81 in the longitudinal direction X, thereby further increasing the absorption. The hemagglutinating agent used for the hemagglutinating fiber of the present invention is one having the effect of agglutinating red blood cells in the blood. The red blood cells agglutinated by the blood cell agglutination agent become a clot. As the blood cell agglutination agent, it is preferable to act so as to agglutinate red blood cells in the blood to form a clot and separate it from plasma components. As a hemagglutinating agent, a cationic polymer is useful. The reason is as follows. A red blood cell has a red blood cell membrane on its surface. The red blood cell membrane has a two-layer structure. The two-layer structure includes a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer. The lipid membrane exposed on the surface of red blood cells contains a protein called a glycophorin. Blood group glycoproteins have a sugar chain bonded to a sugar with an anionic charge called sialic acid at its end. As a result, red blood cells can be treated as colloidal particles having an anionic charge. For agglutination of colloidal particles, agglutinating agents are usually used. Considering that red blood cells are anionic colloidal particles, the use of a cationic substance as an agglutinating agent is advantageous in terms of neutralizing the electric double layer of red blood cells. In addition, if the agglutinating agent has a polymer chain, entanglement of the polymer chains of the agglutinating agent adsorbed on the surface of the red blood cells easily occurs, thereby promoting aggregation of the red blood cells. Furthermore, when the agglutinating agent has a functional group, it is preferable that the aggregation of red blood cells is promoted by the interaction between the functional groups. Hemagglutination agents (cationic polymers) can generate red blood cell agglomerates in menstrual blood through the above mechanism. The preferred hemagglutination agent used in the present invention is particularly preferably one having at least two red blood cell agglutination while maintaining blood fluidity when 1000 ppm of a measurement sample agent is added to simulated blood. Agglomerates are formed. The above-mentioned "state for maintaining the fluidity of blood" means a state in which 10 g of simulated blood to which 1000 ppm of a measurement sample agent is added is added to a spiral mouth bottle ("Spiral mouth tube No. 4" manufactured by Maruemu, Diameter 14.5 mm, body diameter 27 mm, total length 55 mm), and when the spiral mouth bottle containing the simulated blood is turned 180 degrees, more than 80% of the simulated blood sheds in 5 seconds. The so-called simulated blood refers to a viscosity of 8 mPa measured using a B-type viscometer (model TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C, 60 seconds).・ S method is to prepare defibrillated horse blood (manufactured by Nippon Biotest Laboratories Co., Ltd.) with blood cell and plasma ratios. Whether the "two or more red blood cells agglomerate to form a clot" as described above is determined as follows. That is, the above-mentioned simulated blood to which the 1000 ppm measurement sample was added was diluted to 4000 times with physiological saline, and a laser diffraction / scattering particle size distribution measuring device (model: LA-950V manufactured by HORIBA Corporation was used. Measurement conditions: flow (Groove measurement, cycle speed 1, no ultrasonic wave), when the average median particle diameter of the volume particle diameter measured at a temperature of 25 ° C is 10 μm or more, judge: "2 More than one red blood cell agglutinates to form a clot. " The hemagglutination agent used in the present invention is a single compound that meets the above-mentioned properties or a plurality of combinations of single compounds that meet the above-mentioned properties, or an agent that can exhibit the above-mentioned properties by a combination of a plurality of compounds (which can exhibit erythrocyte aggregation). That is, the term "hemagglutination agent" refers to an agent that is limited to those having a hemagglutination effect according to the above definition. Therefore, when a hemagglutinating agent contains a third component that does not meet the above definition, it is expressed as a hemagglutinating agent composition to distinguish it from a hemagglutinating agent. As the hemagglutination agent used in the present invention, those containing a cationic polymer are preferred. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimethylammonium chloride starch. In addition, the hemagglutination agent used in the present invention may include a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate as a cationic polymer. In the present invention, the so-called "quaternary ammonium salt" includes a compound having a positive monovalent charge at the position of a nitrogen atom, or a compound that generates a positive monovalent charge by neutralizing a position at the nitrogen atom, as its specific Examples include a salt of a quaternary ammonium cation, a neutralizing salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The "quaternary ammonium site" described below is also used with the same meaning, and it is a site that is positively charged in water. In the present invention, the term "copolymer" refers to a polymer obtained by copolymerization of two or more polymerizable monomers, and includes both a binary copolymer and a ternary copolymer. In the present invention, the "polycondensate" means a polycondensate obtained by polymerizing a polycondensate containing two or more monomers. In the case where the hemagglutinating agent used in the present invention includes a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as a cationic polymer, the hemagglutinating agent may be Any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, and a quaternary ammonium salt polycondensate may be included, or a combination of any two or more of them may be included. Moreover, a quaternary ammonium salt homopolymer may be used individually by 1 type, and may be used in combination of 2 or more type. Similarly, a quaternary ammonium salt copolymer can be used individually by 1 type or in combination of 2 or more types. Furthermore, similarly, a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types. Furthermore, in the present specification, the "hemagglutination agent" refers to a single compound or a plurality of combinations of the single compounds that can agglutinate red blood cells of the blood, or a combination of a plurality of compounds that exhibits agglutination of red blood cells. Agent. That is, the so-called hemagglutination agent is, in the final analysis, an agent limited to those having a hemagglutination effect. Therefore, when the third component is included in the blood agglutinating agent, it is expressed as a blood agglutinating agent composition to distinguish it from the blood agglutinating agent. In addition, the "single compound" mentioned here refers to a concept including compounds having the same compositional formula but different molecular weights due to different numbers of repeating units. Among the above-mentioned various cationic polymers, in particular, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate is preferable in terms of the adsorbability to red blood cells. In the following description, for convenience, the quaternary ammonium salt homopolymer, quaternary ammonium salt copolymer, and quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer". A quaternary ammonium salt homopolymer is obtained by polymerizing a quaternary ammonium salt homopolymer using one type of polymerizable monomer having a quaternary ammonium site. On the other hand, a quaternary ammonium salt copolymer is obtained by using at least one polymerizable monomer having a quaternary ammonium site and optionally using at least one polymerizable polymer having no quaternary ammonium site. Monomer, etc. to copolymerize. That is, the quaternary ammonium salt copolymer is obtained by copolymerizing two or more polymerizable monomers having a quaternary ammonium site, or using one or more polymerizable monomers having a quaternary ammonium site. And one or more polymerizable monomers which do not have a quaternary ammonium site and are obtained by copolymerizing them and the like. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by polymerizing these condensates by using a condensate containing one or more monomers having a quaternary ammonium moiety. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing a condensate of two or more monomers having a quaternary ammonium site, or using a monomer containing one or more types of quaternary ammonium sites and A polycondensation product of one or more monomers having no quaternary ammonium site, and obtained by polycondensation. The quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium site. The quaternary ammonium site can be generated by quaternary ammonium of a tertiary amine using an alkylating agent. Alternatively, the tertiary amine can be dissolved in an acid or water and produced by neutralization. Alternatively, it can be generated by quaternary ammoniumation using a nucleophilic reaction including a condensation reaction. Examples of the alkylating agent include a halogenated alkyl group and a dialkyl sulfate such as dimethyl sulfate and dimethyl sulfate. Among these alkylating agents, if a dialkyl sulfate is used, it is preferable not to cause the problem of corrosion that may occur when a halogenated alkyl group is used. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. In particular, if a quaternary ammonium salt polymer obtained by quaternizing a tertiary amine site with an alkylating agent is used, the electric double layer of red blood cells can be reliably neutralized, which is preferable. The quaternary ammonium reaction using a nucleophilic reaction including a condensation reaction can occur as a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin, and a cyclization reaction of dicyandiamide and diethylene triamine. As described above, the molecular weight of the cationic polymer used as a blood agglutinating agent is preferably 2,000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more, from the viewpoint of efficiently forming agglomerates of red blood cells. , And more preferably more than 150,000. When the molecular weight of the cationic polymer is equal to or higher than this value, the entanglement of cationic polymers between red blood cells or the cross-linking of cationic polymers between red blood cells is sufficiently generated, and agglomerates of red blood cells are effectively generated through blood. , The effect of suppressing the spread of blood is improved, so it is better. The upper limit of the molecular weight is preferably 30 million or less, more preferably 22 million or less, and even more preferably 10 million or less. When the molecular weight of the cationic polymer is equal to or less than these values, the cationic polymer is well dissolved in menstrual blood. Separation of menstrual blood into red blood cells and plasma effectively generates agglomerates of red blood cells. Plasma is efficiently absorbed by the superabsorbent polymer, the amount of absorption and the speed of absorption are increased, and the movement of menstrual blood from the inside of the leak prevention tank to the outside is suppressed and maintained From the viewpoint of good leak-proof performance, the molecular weight of the cationic polymer is preferably 2,000 to 30 million, more preferably 10,000 to 22 million, and still more preferably 150,000 to 10 million. Furthermore, if the molecular weight of the cationic polymer is 10,000 or more and 150,000 or less, especially 10,000 or more and 120,000 or less, the menstrual blood agglomerates will not be hypertrophized and formed into an appropriate size. Can block the pulp fiber voids contained in the absorbent core or the voids in the pores of the chipped material. After the cationic polymer is well dissolved in menstrual blood, the absorbent core and chipped can be maintained to a high degree The permeability of menstrual blood in the material is better in this respect. The molecular weight of the cationic polymer can be controlled by appropriately selecting its polymerization conditions. In addition, two or more cationic polymers having different molecular weights may be combined in the above molecular weight range. The molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows. The molecular weight referred to in the present invention means a weight average molecular weight. As the column, a column temperature of 40 ° C was used, and a protection column α manufactured by Tosoh Co., Ltd. and an analysis column α-M were connected in series. The detector uses RI (Refractive Index). As a measurement sample, 1 mg of a treatment agent (quaternary ammonium salt polymer) to be measured was dissolved in 1 mL of the eluate. As the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an eluent obtained by dissolving 150 mmol / L of sodium sulfate and 1% by mass of acetic acid in water is used. Copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate use amylopectin with a molecular weight of 5900, amylopectin with a molecular weight of 47300, amylopectin with a molecular weight of 212,000, and amylopectin with a molecular weight of 788,000. An amylopectin mixture prepared by dissolving 2.5 mg of 10 mL of the eluate as a molecular weight standard. The copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate was measured at a flow rate: 1.0 mL / min and an injection amount: 100 μL. Except for copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate, 50 mmol / L of lithium bromide and 1% by mass of acetic acid were dissolved in ethanol: water = 3: 7 (volume ratio). Of eluate. Except for copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate, polyethylene glycol (PEG) with a molecular weight of 106, PEG with a molecular weight of 400, PEG with a molecular weight of 1470, PEG with a molecular weight of 6,450, and a molecular weight of 5 are used. Polyethylene oxide (PEO) with a molecular weight of 10,000, PEO with a molecular weight of 235,000, and PEO with a molecular weight of 875,000 were each dissolved in 20 mL of a PEG-PEO mixture as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the measurement was performed at a flow rate: 0.6 mL / min and an injection amount: 100 μL. From the viewpoint of efficiently forming agglomerates of red blood cells, the cationic polymer is preferably water-soluble. In the present invention, the so-called "water-soluble" refers to the following properties: in a 100 mL glass beaker (5 mmΦ), a powdery cationic polymer having a thickness of 0.05 g or less and a film thickness of 0.5 mm or less is added When mixing in 50 mL of ion-exchanged water at 25 ° C, put a stir bar with a length of 20 mm and a width of 7 mm, and stir it at 600 rpm using a magnetic stirrer HPS-100 manufactured by AS ONE Co., Ltd. Dissolved in water within 24 hours. Furthermore, in the present invention, as further preferable solubility, it is preferable that the entire amount is dissolved in water within 3 hours, and it is more preferable that the entire amount is dissolved in water within 30 minutes. The cationic polymer is preferably a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer is preferably a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium site is preferably present in the side chain. In this case, if the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium portion existing in the side chain is smoothly adsorbed on the surface of the red blood cells. Of course, in the present invention, the main chain and the side chain of the cationic polymer may be bonded at two or more points. In the present invention, "bonded at one point" refers to a single bond between one of the carbon atoms constituting the main chain and one carbon atom at the end of the side chain. The term "bonded with two or more points" refers to a single bond between two or more of the carbon atoms constituting the main chain and two or more carbon atoms at the end of the side chain. In the case where the cationic polymer has a structure having a main chain and a plurality of side chains bonded thereto, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto In this case, the carbon number of each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the carbon number of the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and even more preferably 6 or more and 8 or less. The so-called carbon number of the side chain refers to the carbon number of the quaternary ammonium site (cation site) in the side chain. Even if the anion serving as a counter ion contains carbon, its carbon is not included in the count. In particular, when the carbon number from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen in the side chain is in the above range, the position when the quaternary ammonium salt polymer is adsorbed on the surface of the red blood cell The resistance is reduced, so it is better. When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include polymers of vinyl-based monomers having a quaternary ammonium site or a tertiary amine site. When a vinyl monomer having a tertiary amine moiety is polymerized, the quaternary ammonium salt obtained by quaternizing the tertiary amine moiety with an alkylating agent before and / or after the polymerization is used. The polymer is either a tertiary amine neutralization salt obtained by neutralizing a tertiary amine site with an acid before and / or after polymerization, or a tertiary amine having a cation in an aqueous solution after polymerization. Examples of the alkylating agent or the acid are as described above. In particular, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1. [Chemical 1] Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine and the like. In addition, poly (2-methacryloxyethyldimethylamine quaternary salt), and poly (2-methyl Propylene ethoxyethyl trimethyl ammonium salt), poly (2-methacryl ethoxy ethyl dimethyl ethyl ammonium methyl sulfate), poly (2-propylene ethoxy ethyl dimethyl methoxide) Quaternary amine salt), poly (2-propenyloxyethyltrimethylamine quaternary salt), poly (2-propenyloxyethyldimethylethylammonium ethyl sulfate), poly ( 3-dimethylaminopropylacrylamide quaternary salt), dimethylaminoethyl methacrylate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylamine Propyl acrylamide, polyfluorene and the like. On the other hand, examples of the homopolymer having a side chain and a main chain having a quaternary ammonium moiety at two or more points include polydiallyldimethylammonium chloride and polydiallylamine salt. Acid salt. In the case where the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, as the copolymer, two or more polymerizable monomers used for the polymerization of the above-mentioned quaternary ammonium salt homopolymer can be obtained by copolymerization. Of copolymers. Alternatively, as the quaternary ammonium salt copolymer, one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer and one or more polymerizable monomers having no quaternary ammonium site can be used. Copolymer obtained by copolymerization. Furthermore, other polymerizable monomers such as -SO may be used in addition to or instead of the vinyl polymerizable monomer. 2 -Wait. The quaternary ammonium salt copolymer may be a binary copolymer or a terpolymer or higher as described above. In particular, from the viewpoint of efficiently forming agglomerates of red blood cells, the quaternary ammonium salt copolymer preferably has a repeating unit represented by the above formula 1 and a repeating unit represented by the following formula 2. [Chemical 2] As the polymerizable monomer having no quaternary ammonium site, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, in particular, by using a cationic polymerizable monomer or a non-ionic polymerizable monomer, the quaternary ammonium salt copolymer does not cause a charge offset with the quaternary ammonium site, so that Can effectively produce agglutination of red blood cells. As an example of the cationic polymerizable monomer, examples of the cyclic compound having a nitrogen atom having a cation under a specific condition include vinylpyridine and the like, and having a nitrogen having a cation under a specific condition in the main chain. The atomic linear compound includes a condensation compound of dicyandiamide and diethylene triamine, and the like. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, styrenesulfonic acid, and salts of these compounds. On the other hand, examples of the nonionic polymerizable monomer include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, and methacrylic acid. Hydroxyethyl ester, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, and the like. These cationic polymerizable monomers, anionic polymerizable monomers, or non-ionic polymerizable monomers may be used alone, or any two or more of them may be used in combination. Further, two or more cationic polymerizable monomers may be used in combination, two or more anionic polymerizable monomers may be used in combination, or two or more nonionic polymerizable monomers may be used in combination. . The molecular weight of the quaternary ammonium salt copolymer obtained by copolymerization using a cationic polymerizable monomer, an anionic polymerizable monomer, and / or a nonionic polymerizable monomer as the polymerizable monomer is preferably 1,000 as described above. 10,000 or less, particularly preferably 5 million or less, especially 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below). As the polymerizable monomer having no quaternary ammonium site, a polymerizable monomer having a functional group capable of hydrogen bonding can also be used. By using such a polymerizable monomer for copolymerization, when using the quaternary ammonium salt copolymer thus obtained to agglutinate red blood cells, it is easy to form harder agglomerates, and the absorption performance of the superabsorbent polymer is more difficult to be hindered. . Examples of the functional group capable of hydrogen bonding include -OH and -NH 2 , -CHO, -COOH, -HF, -SH, etc. Examples of the polymerizable monomer having a functional group capable of hydrogen bonding include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, Ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, and the like. In particular, the adsorption state of quaternary ammonium salt polymers to erythrocytes such as hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, and methacrylamide, which have a strong hydrogen bond effect. Stable and better. These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types. As the polymerizable monomer having no quaternary ammonium site, a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same advantageous effects as described above when a polymerizable monomer having a functional group capable of hydrogen bonding can be achieved, that is, a harder one that easily produces red blood cells The effect of agglomerates. Examples of the functional group capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl, phenyl, alkylnaphthyl, and fluorinated alkyl. Examples of the polymerizable monomer having a functional group capable of hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, and propyl acrylate. , Butyl methacrylate, butyl acrylate, styrene, etc. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, and the like, which strongly exert hydrophobic interactions and do not significantly reduce the solubility of the quaternary ammonium salt polymer, due to quaternary ammonium The adsorption state of the salt polymer to red blood cells is preferably stabilized. These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types. The mole of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer are preferably adjusted so that red blood cells pass through the quaternary ammonium salt. The copolymer is sufficiently aggregated. In particular, the molar content of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and even more preferably 32 mol%. The above is more preferably 38 mol% or more. It is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and still more preferably 56 mol% or less. Specifically, the molar content of the polymerizable monomer having a quaternary ammonium site is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, and more preferably It is preferably 32 mol% or more and 65 mol% or less, and still more preferably 38 mol% or more and 56 mol% or less. In the case where the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, as the polycondensate, a polycondensate obtained by using the above-mentioned monomer having one or more quaternary ammonium sites can be used Polymerized by condensation. Specific examples include a dicyandiamide / diethylene triamine condensation polymer, a dimethylamine / epichlorohydrin condensation polymer, and the like. The above-mentioned quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or a copolymerization method of a vinyl-based polymerizable monomer. Examples of the polymerization method include radical polymerization, living radical polymerization, living cationic polymerization, living anionic polymerization, coordination polymerization, ring-opening polymerization, and polycondensation. The polymerization conditions are not particularly limited as long as the conditions for obtaining a quaternary ammonium salt polymer having a target molecular weight, flow potential, and / or IOB (Inorganic Organic Balance, Inorganic and Organic Balance) value are appropriately selected. The cationic polymer described in detail above is an example of the above-mentioned "Excellent Hemagglutination Agent", and its effects can be referred to Japanese Patent Application No. 2015-239286 and Japanese Patent Laid-Open Publication of Japanese Published Gazette as the application. Examples 1 to 45 described in International Publication No. 2016-093100 and International Publication No. 2016/093233 based on this application as a priority claim. In addition, the hemagglutination agent used in the present invention may be one or more types of third component in addition to polycation (cationic polymer), such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, The form of a composition (hemagglutinating agent composition) of other ingredients such as a skin care agent. As the solvent, water-soluble organic solvents such as water and saturated aliphatic monohydric alcohols having 1 to 4 carbons, or mixed solvents of the water-soluble organic solvents and water, and the like can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol, and the like can be used. As the fragrance, a fragrance having a green herbal flavor, a plant extract, a citrus extract, and the like described in Japanese Patent No. 4776407 can be used. As the antibacterial / deodorizing agent, an mayenite-like mineral containing a metal having antibacterial properties described in Japanese Patent No. 4526271, and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928 can be used. Porous polymer formed by polymer polymerization, quaternary ammonium salts described in Japanese Patent No. 4,651,392, activated carbon, clay minerals, and the like. As the skin care agent, plant extracts, collagen, natural moisturizing ingredients, moisturizers, keratin softeners, anti-inflammatory agents, etc. described in Japanese Patent No. 4084278 can be used. The proportion of the cationic polymer in the blood cell agglutinant composition is preferably 1% by mass or more, more preferably 3% by mass or more, and even more preferably 5% by mass or more. The content is preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 10% by mass or less. By setting the ratio of the cationic polymer in the blood cell agglutinant composition to be within this range, an effective amount of the cationic polymer can be imparted to the absorbent article. As mentioned above, although this invention was demonstrated, this invention is not limited to the said embodiment, It can change suitably in the range which does not deviate from the meaning of this invention. For example, the arrangement of the hemagglutination agent in the entire area or a part of the part overlapping the absorbent core in the lower member of the skin-side encapsulating core material is not limited to those in the first embodiment or the second embodiment, as long as it can form and prevent The agglutinating agent disposition portion in which the whole or a part of the drain groove 8 overlaps can be set to an arbitrary state. For example, the agglutinating agent disposition portion may be provided in such a manner that the leakage preventing groove 8 overlaps across the entire circumference, or an agglutinating agent disposing portion may be formed in which only one or both of the front leakage preventing groove 82 and the rear leakage preventing groove 83 overlap. In addition, a pair of side leak-proof grooves 81, one or both of the front leak-proof grooves 82 and the rear leak-proof grooves 83 may be formed as an agglutinating agent disposition portion, or the entire length of the side leak-proof grooves 81 may be formed instead. The agglutinating agent disposition portion in which only the central arc-shaped portion of the side leak-proof groove overlaps. In addition, the lower member containing the hemagglutinating agent may be a member other than the skin-side encapsulating material, such as an absorbent core or a non-skin-side encapsulating material, or two or more lower members may include a hemagglutinating agent. For example, it may be any two or more of the skin-side encapsulating core material, the absorptive core body, and the non-skin-side encapsulating core material, or it may be across the skin side-enclosing core material, the absorptive core, and the non-skin side-encapsulating core material. All methods are configured with a hemagglutinating agent. In addition, the blood cell agglutinating agent may be contained in the lower member, and is not excluded to be contained in the front sheet. In addition, the absorbent article may be one without a side leak-proof sheet and a leak-proof mechanism using the same, or may be one without a side flap. In addition, the absorbent article of the present invention may be a sanitary pad (vaginal secret pad) or the like in addition to the menstrual tampon. Regarding the embodiment of the present invention described above, the present invention further discloses the following additional notes (absorbent articles, etc.). <1> An absorbent article, which is an absorbent article for menstrual blood absorption, comprising: a front sheet that forms liquid permeability on the skin-facing side, a back sheet that forms a non-skin facing surface, and is disposed on the The absorbent body between the two sheets has a longitudinal direction along the front and back direction of the wearer and a transverse direction orthogonal to the longitudinal direction. On the side opposite to the skin, the front sheet is trapped into the side of the absorbent body. The anti-leak groove extends continuously on both sides along the longitudinal direction, and includes a hemagglutinating agent in a lower member disposed closer to the back sheet than the front sheet, and the hemagglutinating agent is disposed in the lower member. The range has an overlapping portion with the above-mentioned side leak-proof groove. <2> The absorbent article according to <1>, in which the side leak-proof groove has a central circle that is convexly curved toward the laterally outward side of the excretory portion facing the excretory portion of the wearer. Arc. <3> The absorbent article according to <2>, each of which includes a front arc-shaped portion and a rear arc-shaped portion having a plan shape that is convexly curved toward the laterally outer side before and after the central arc-shaped portion. And the connection portion between the central arc-shaped portion and the front arc-shaped portion and the connection portion between the central arc-shaped portion and the rear arc-shaped portion become a pair of side leak-proof grooves with a narrowing distance. unit. <4> The absorbent article according to <3>, wherein the absorbent article has a front side portion disposed closer to the wearer's front side than the excretory portion facing portion, and a rear side of the wearer facing the excretory portion facing portion. The rear square portion is arranged, and the front arc-shaped portion and the rear arc-shaped portion are located at the front portion and the rear portion, respectively. <5> The absorbent article according to any one of <2> to <4>, wherein the longitudinal full length of the central arc-shaped portion of the pair of lateral leak-proof grooves overlaps the aggregating agent disposition portion. <6> The absorbent article according to <1>, in which the side leakage-preventing groove has an arc curved convexly toward the inner side in the lateral direction at the portion facing the excretion portion of the wearer.状 部。 State. <7> The absorbent article according to any one of <1> to <6>, wherein the lower member is a member adjacent to the front sheet in a thickness direction of the absorbent article. <8> The absorptive article according to any one of <1> to <7>, in which the range in which the hemagglutination agent is disposed in the lower member and the overlapping portion of the side leak-proof groove overlaps The amount of the hemagglutinating agent per unit area is 6 g / m 2 Above 80 g / m 2 the following. <9> The absorbent article according to any one of <1> to <8>, wherein the hemagglutination agent in the repetitive portion is present in an amount per unit area more than the side leak-proof groove The amount of the hemagglutinating agent present per unit area of the overlapping portion. <10> The absorbent article according to any one of <1> to <9>, wherein the hemagglutination agent has a cationic polymer having a weight average molecular weight of 2,000 to 30 million. <11> The absorbent article according to <10>, wherein the weight-average molecular weight of the hemagglutination agent is 10,000 or more and 22 million or less, preferably 150,000 or more and 10 million or less. <12> The absorbent article according to any one of <2> to <11>, in which a second leakage prevention line juxtaposed with the lateral leakage prevention groove in the lateral direction is formed in the facing portion of the excretion portion. groove. <13> The absorbent article according to <12>, in which the side leak-proof groove has a central circle convexly curved toward the laterally outward side of the excretory portion facing the excretory portion of the wearer. The second leak-proof groove is formed in an arc-shaped portion so as to be parallel to the central arc-shaped portion in a lateral direction. <14> The absorbent article according to <12> or <13>, wherein the second leakproof groove is formed on a laterally outer side of the lateral leakproof groove. <15> The absorbent article according to <13> or <14>, wherein the central arc-shaped portion, the second leak-proof groove, and the agglutinating agent disposing portion including the blood cell agglutinating agent are continuously provided between the span and the gap. overlapping. <16> The absorbent article according to <13> or <14>, in which the above-mentioned blood cell agglutinating agent is separated from the central arc-shaped portion and the second leakage-preventing groove by being separated by a gap in the lateral direction. The agglutinating agent placement portions overlap. <17> The absorbent article according to any one of <1> to <16>, comprising a front leakproof groove connecting the ends of the pair of lateral leakproof grooves to the front portion side, and An annular leak-proof groove is formed after the rear leak-proof groove is connected to the rear part side. <18> The absorbent article according to any one of <1> to <17>, wherein the arrangement portion of the blood cell agglutinating agent is 50% or more and 100% of the longitudinal length of the pair of lateral leak-proof grooves % Or less, preferably 70% or more and 100% or less overlap. <19> The absorbent article according to any one of <1> to <18>, wherein the absorbent system includes an absorbent core and a core material covering the absorbent core, and the blood cells are as described above. An agglutinating agent is contained in the encapsulating material. <20> The absorbent article according to <19>, wherein the absorbent core comprises a mixed fiber stack of pulp fibers and a superabsorbent polymer. <21> The absorbent article according to <19> or <20>, in which the entire area of the skin-side portion of the skin-opposing surface of the core material covering the absorbent core is an agglutinating agent containing a hemagglutinating agent Configuration Department. <22> The absorbent article according to any one of <1> to <21>, wherein the absorbent article is a menstrual tampon. <23> An absorbent article, which is an absorbent article for menstrual blood absorption, comprising: a front sheet that forms liquid permeability on the skin-facing side, a back sheet that forms a non-skin facing surface, and is disposed on the The absorbent body between the two sheets has a longitudinal direction along the front and back direction of the wearer and a transverse direction orthogonal to the longitudinal direction. On the side opposite to the skin, the front sheet is trapped into the side of the absorbent body. The anti-leak groove extends continuously on both sides along the longitudinal direction, and a lower member disposed closer to the back sheet than the front sheet includes a cationic polymer, and the cationic property is disposed in the lower member. The range of the polymer overlaps the above-mentioned side leak-proof groove. <24> The absorbent article according to <23>, wherein the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate. <25> The absorbent article according to <24>, wherein the molecular weight of the cationic polymer is 2,000 to 30 million. [Examples] Hereinafter, the present invention will be described in more detail with examples. However, the scope of the present invention is not limited in any way by this embodiment. [Example 1] A menstrual tampon of the form shown in FIG. 1 was produced, and this was set as a sample of Example 1. The thickness of menstrual tampons was set to 4.2 mm. As the absorbent body 4, a mixed fiber stack (absorbent core) containing wood pulp fibers and a super absorbent polymer was used, and the basis weight was 16 g / m 2 A thin paper (toilet paper) having a thickness of 0.3 mm is coated with the mixed fiber stack. The basis weight of wood pulp fibers in the mixed fiber stack is 300 g / m 2 , The basis weight of the superabsorbent polymer is 56 g / m 2 . As the superabsorbent polymer, a general-purpose superabsorbent polymer suitable for sanitary products manufactured by Nippon Catalytic Corporation is used. The following formula was used to prepare a hemagglutinating agent as an aqueous solution, 5 g was dissolved in 100 g of ion-exchanged water, and the solution was impregnated over the entire surface of the encapsulating material in the absorbent body 4 at 30 ° C and 10% RH. It was left to stand for 24 hours to dry, and the amount of the hemagglutinating agent per unit area contained in the dried core material was 12 g / m. 2 By.・ Unisence FPA1002L (Senka Co., Ltd .; polydiallyl dimethyl ammonium chloride (weight average molecular weight: 600,000, flow potential: 7856 μeq / L)) of hemagglutination agent [Example 2] As FIG. 3 The form shown is that per unit area of the hemagglutinating agent per unit area contained in the dried encapsulation sheet, per unit of the hemagglutinating agent in the repeating portion overlapping with the longitudinally extending portion of the leakproof groove The area present becomes 50 g / m 2 And make the amount of hemagglutinating agent per unit area of the other parts of the encapsulation material 12 g / m 2 Other than that, a menstrual tampon was produced in the same manner as in Example 1, and it was set as a sample in Example 2. [Examples 3 and 4] In Example 1, the menstrual tampons were produced in the same manner except that the formula of the hemagglutinating agent was replaced with the following.・ Example 3: Polydiallyl dimethyl ammonium chloride (weight average molecular weight: 150,000) obtained by drying under the trade name Merquat100 manufactured by Lubrizol Japan. ・ Example 4: Trade name manufactured by Nittobo Medical. Polydiallyldimethylammonium chloride obtained by drying PAS-H-5L (weight average molecular weight: 30,000, flow potential 7447 μeq / L, IOB2.1) [Example 5] The formation is shown in Figure 8 A menstrual tampon was prepared in the same manner as in Example 1 except that the leak-proof groove was formed in a linear shape extending in the longitudinal direction across both sides of the excretion position portion P, and was set as a sample in Example 5. [Comparative Example 1] A menstrual tampon was produced in the same manner as in Example 1 except that the hemagglutination agent was not coated on the core material, and this was used as a sample of Comparative Example 1. [Evaluation Test] The menstrual tampons of Examples and Comparative Examples were evaluated for leak-proofness by the following methods. The results are shown in Table 1 below. The simulated blood (viscosity 8 mPa · s) was used as the simulated blood. <Evaluation method of leakproofness> Each menstrual tampon is repeatedly worn until the gap between the surface material and the absorbent body is fixed to the inclined surface at an angle of 45 ° with respect to the horizontal plane with the side of the front sheet 2 facing upward on. Over a period of 10 seconds, 3 g of simulated blood was dripped on the excretion site portion of the menstrual napkin in this state. After standing for 3 minutes, observe the opposite side of the skin of each tampon, and visually observe whether the liquid spreads across the leakproof wall. In the case where the liquid has spread beyond the leakproof tank, 3 g of simulated blood is added dropwise for 10 seconds and left for 3 minutes. This operation is repeated until the liquid spreads beyond the leakproof tank, and is evaluated according to the following criteria. A: 12 g or more B: 6 g or more to less than 12 g C: 6 g or less According to the evaluation of the leakproofness shown in Table 1, it was found that the menstrual napkins of Examples 1 to 5 were compared with Comparative Example 1 Compared with the menstrual period sanitary napkins, the effect of suppressing the diffusion of the liquid produced by the leakproof trough is improved. In particular, a leak-proof groove having a curved shape that is convex or convex at the excretion position portion P (Examples 1 to 4) shows a higher level than a leak-proof groove having a linear shape (Example 5). Leak-proof. The above test is supposed to generate external force due to the action during wearing, etc. to cause a gap between the surface material of the leak-proof groove and the pressure-contact portion of the absorbent body, and forcibly make the surface material and absorbent body in the leak-proof groove of each menstrual napkin It peeled and evaluated. [Table 1] [Example 6] A menstrual tampon in the form shown in Fig. 8 was prepared and used as a sample of Example 6. Specifically, as shown in FIG. 8, except that the pair of side leak-proof grooves 81 and 81 are linearly formed, the whole area of the chip-coated material is coated with hemagglutination in the same manner as in Example 1. The menstrual tampon was used as the sample of Example 6. [Comparative Example 2] A menstrual tampon was produced in the same manner as in Example 6 except that the hemagglutinating agent was not coated on the core material, and this was used as a sample of Comparative Example 2. <Static Maximum Absorption Amount> Fix a sample of menstrual tampon on an acrylic plate, inject 3 g of simulated blood from the excretion site, and let it stand for 3 minutes after the liquid injection is completed. After that, it will become 50 g per square centimeter. A 1 minute load was applied to the liquid excretion position. This operation was repeated thereafter, and the liquid was exuded from the side wings of the menstrual tampon, and it was set as the static maximum absorption amount. <Dynamic diffusion length> A sample of menstrual tampons is fixed to menstrual shorts and worn on a dynamic model of the human body. The dynamic model was started to walk. One minute after the start of the walk, 3 g of simulated blood was injected from the liquid excretion site, and a total of 3 minutes of walking was performed after the start of the walk (first time). After repeating this operation twice, remove the tampon from the dynamic model, and measure the length of the tampon in the horizontal direction and the length of the tampon in the portion of the tampon that is colored due to the simulated blood, and set it as the horizontal and vertical dynamic diffusion. length. [Table 2] As can be seen from the evaluation of the static maximum absorption amount shown in Table 2, the static maximum absorption amount of the menstrual napkin of Example 6 was higher than that of the comparative example 2 of the menstrual napkin. In addition, it can be seen that the effect of suppressing the diffusion of the liquid generated by the leak prevention tank is improved. Furthermore, from the evaluation of the dynamic diffusion length, it can be seen that, compared with Comparative Example 2, the diffusion in Example 6 was controlled in the lateral direction and diffused in the longitudinal direction. From the results of the above evaluation, it can be seen that the diffusion suppression effect of the liquid generated by the leakproof tank is improved, and the absorption performance is improved. [Industrial Applicability] According to the absorbent article of the present invention, the movement of menstrual blood from the inside to the outside of the leak prevention groove is suppressed, and a good leak prevention performance can be maintained.